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BACKGROUND: Antiretroviral therapy (ART), notably efavirenz and lopinavir, have been 
associated with metabolic abnormalities known to increase cardiovascular risk. Efavirenz and 
lopinavir pharmacokinetics demonstrate considerable interindividual variability, which in part, 
may be explained by host genetic factors. Mitochondrial DNA (mtDNA) variation influences 
ART related metabolic complications. However, the associations between genetic polymorphisms 
and pharmacokinetics of antiretroviral drugs, and their associations with metabolic complications, 
are incompletely understood. We explored associations of mitochondrial DNA (mtDNA) 
haplogroups and ART related metabolic complications, characterized relationships between 
genetic polymorphisms and plasma efavirenz concentrations, and investigated associations 
between plasma efavirenz/lopinavir concentrations and lipid and glucose concentrations in HIV-
infected Black South Africans.  
METHODS: We collected clinical and laboratory data from HIV infected patients on ART from 
Cape Town. We sequenced the mitochondrial genome and determined African mtDNA 
haplogroups. We genotyped 241 polymorphisms in genes potentially relevant to efavirenz 
metabolism and transport. We measured steady state efavirenz and lopinavir concentrations and 
used regression analyses to determine associations with metabolic parameters.  
RESULTS: In multivariate regression analyses adjusting for age, sex and ART duration African 
mtDNA subhaplogroup L3e1 (adjusted OR (aOR) 3.16, p=0.03) and exposure to 
lopinavir/ritonavir (aOR 2.98, p=0.05) were independently associated with hypertriglyceridemia. 
There were no significant associations between mtDNA haplogroups and cholesterol, 
dysglycaemia, hyperlactataemia, lipoatrophy, or peripheral neuropathy.  
A model that included composite genotype (CYP2B6 516/983/15582) best predicted efavirenz 
concentrations (β=0.28, p=2.4 x10-11). Among individual CYP2B6 polymorphisms, 516G→T best 
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predicted efavirenz concentrations (β =0.22, p=1.27x10-6). There were also associations with 
983T→C (β =0.27, p=0.002), and 15582C→T (β=0.11, p=0.04). No other polymorphisms were 
independently associated with efavirenz concentrations. 
In multivariate regression analyses adjusting for age, sex, BMI, and ART duration log10 
transformed efavirenz concentrations were significantly associated with total cholesterol (β=1.34, 
p<0.001), LDL cholesterol (β=0.62, p=0.012), HDL cholesterol (β=0.46, p<0.001), triglycerides 
(β = 0.58, p=0.022), fasting glucose (β=0.60, p=0.017), and 2-hour glucose concentrations 
(β=1.14, p=0.010).  
We found no associations between lopinavir concentrations and metabolic parameters. 
CONCLUSIONS: Our findings improve the understanding of genetic determinants of efavirenz 
plasma exposure in an African population, and provide new insights into host factors associated 
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Sub-Saharan Africa carries the highest global burden of people living with HIV, with an 
estimated 26 million living in this region.1,2 Efforts to control the epidemic include up-scaling 
access to antiretroviral therapy (ART) in low to middle income countries.1 In 2014, 10.7 million 
people were accessing ART, with 5/7 people on ART living in Sub-Saharan Africa.1,2 Improved 
access to ART has led to an appreciable decline in the incidence of new HIV infections, as well 
as AIDS related deaths.1  
South Africa is home to more people living with HIV than any other country.3 In the 2012 
household survey, the HIV prevalence in South Africa was estimated at 12.2% (6.4 million 
persons), with the prevalence varying greatly by age, race, sex and province. Over 6.2 million 
black Africans were living with HIV, with the females in their 20s to early 30s being the worst 
affected.3 Of the 6.4 million people living with HIV in South Africa, only just over 2 million 
persons (31.2 %) were exposed to ART.3  
Standard combination antiretroviral therapy (ART) regimens include two nucleoside reverse 
transcriptase inhibitors (NRTIs) with a non-NRTI or a ritonavir-boosted protease inhibitor.4 With 
the improved access to ART and subsequent decline in mortality, HIV-infected patients are living 
longer and diseases associated with aging, such as cardiovascular events, are emerging as major 
concerns for long term HIV management.5 In addition, exposure to ART has been associated with 
metabolic adverse effects such as dyslipidaemia, insulin resistance, dysglycaemia, central fat 
accumulation, peripheral fat loss (lipoatrophy), and peripheral neuropathy.6,7 Of note, the 
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association between metabolic adverse events is not usually a class effect, but more related to 
individual drug exposures.8  
Some of these metabolic adverse events are thought to be dose-related, as evidenced by lower 
cumulative incidence when doses are reduced. However, data linking the metabolic adverse 
events and drug concentrations is limited and sometimes conflicting. For example, our study 
group found no association between stavudine plasma concentrations and lipoatrophy.9 In 
contrast, ter Hosftede et al found such positive association between stavudine and lipoatrophy.9,10 
Pereira et al found a positive correlation between efavirenz plasma concentrations and high-
density lipoprotein (HDL) cholesterol,11 whereas two other studies found no associations.12,13 
Two studies reported a positive correlation between higher lopinavir plasma concentrations and 
triglycerides but not cholesterol,14 or both triglycerides and cholesterol concentrations.15 A few 
more studies have reported no associations between lopinavir or ritonavir plasma and cholesterol 
or triglycerides.13,16-20 These studies are usually small and often not randomized. Therefore, more 
studies are needed to elucidate the pathogenesis of these ART related metabolic complications. 
More studies on the relationships between efavirenz and lopinavir drug concentrations and the 
lipid and glucose concentrations especially relevant in resource-limited settings, where they still 
form key components of the 1st (efavirenz) and 2nd (lopinavir) line regimens.  
There is marked interindividual variability in plasma concentrations of efavirenz and lopinavir, 
which is partly due to variation in genes encoding metabolism and transport.21 Efavirenz is 
metabolized primarily by cytochrome P450 isoenzyme 2B6 (CYP2B6) with minor contributions 
from CYP2A6 and CYP3A4/5, and direct N-glucoronidation from UGT2B7.22 To-date at least 
three loss-of-function CYP2B6 genetic polymorphisms [516G→T (rs3745274)23-27, 983T→C 
(rs283992499),26,28-30 and more recently, 15582C→T (rs4803419)26] have been consistently been 
associated with increased plasma plasma efavirenz concentrations. The marked variability in 
efavirenz concentrations can be partly explained by varying frequencies in these genetic 
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polymorphisms. For example, our group has shown that CYP2B6 516T is about 5 times more 
prevalent in southern Africans than in Caucasians.31 The effect of CYP2B6 983T→C on efavirenz 
concentrations (per allele) is greater than that of CYP2B6 516G→T, but its frequency is far less 
and appears to found only with African ancestry.21,26 The effect of CYP2B6 15582C→T is far less 
than that of CYP2B6 516G→T, but the frequency is high with European and Asian ancestry.26 
These three polymorphisms stratify patients into ten plasma trough concentration subgroups 
across an approximately tenfold range of medians, with the top three classified as slow 
metabolizers.26 Therefore, in patients of African ancestry, where the burden of HIV infection 
largely lies, a high proportion of patients will belong to the slow metabolizer subgroup, with 
resultant higher efavirenz concentrations, which in turn, may be associated with efavirenz related 
metabolic complications.  
On the other hand, lopinavir is metabolized primarily by hepatic cytochrome P450 (CYP) 3A 
isoforms and is a substrate for p-glycoprotein (P-gp), multidrug resistance-associated protein 2 
(MRP2), and solute carrier organic anion transporter family, member 1B1 (SLCO1B1).32 Limited 
studies have found no association between lopinavir plasma concentrations and polymorphisms in 
ABCB1, CYP3A5, CYP2B6 and CYP2D6 genes.33 Recent studies have reported “gain of function” 
(rs11045819) and “loss of function” (rs4149056) variants in SLCO1B1 gene, which may lead to 
low and high plasma concentrations of lopinavir, respectively.32,33 It has been shown that 
polymorphisms in the PXR and CAR genes in sub-Saharan African adults can alter the induction 
of CYP3A4 and CYP2B6 promoter activity thus contributing to the variable nature of lopinavir 
and efavirenz drug interactions, respectively.34 
Several metabolic abnormalities are due to mitochondrial toxicity from NRTI inhibition of 
mitochondrial DNA (mtDNA) polymerase–γ, an essential enzyme for mtDNA replication.6 
Manifestations of mitochondrial toxicity include distal sensory polyneuropathy (DSP), 
hyperlactataemia, lipoatrophy and insulin resistance.35,36 Our collaborators at Vanderbilt have 
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identified associations between mtDNA haplogroups and NRTI related complications. 
Associations between mtDNA haplogroups and other metabolic complications, including 
lipoatrophy and dyslipidaemia have been reported.37,38 In European Americans mitochondrial 
haplogroup T independently increased the risk of DSP.39 In African Americans, conflicting 
results were found regarding the association between African mtDNA sub-haplogroup L1c and 
DSP.40-42  
We hypothesized that antiretroviral pharmacokinetics and pharmacogenomics predict metabolic 
complications (including DSP) of antiretroviral therapy in a well-characterized cohort of HIV-
infected black South Africans. The key research questions addressed in this thesis are listed 
below. 
Key research questions 
The key research questions addressed in this thesis are: 
1. Are efavirenz concentrations associated with lipids and glucose concentrations?  
2. Are lopinavir concentrations associated with lipids and glucose concentrations?  
3. Is the interindividual variability in plasma efavirenz concentrations predicted by genetic 
polymorphisms in CYP2B6, alone or in combination with polymorphisms in additional 
relevant genes (CYP2A6, ABCB1, CYP3A4, CYP3A5 and PXR)?  
4. Are the African mitochondrial DNA (mtDNA) haplogroups associated with toxicity due to 






Antiretroviral treatment program in Cape Town 
South Africa is home to the highest number of people living with HIV infection.1 Prior to the 
antiretroviral roll-out by the National Department of Health in late 2003, access to the 
antiretroviral drugs limited to places where ART clinics were set up by not-for-profit 
organizations like the Doctors Without Borders, enrollment into clinical trials for mother-to-child 
prevention programs or patients paid for the antiretroviral drugs through private medical practice. 
 Since 2004, access to ART has improved dramatically in South Africa.1   The treatment 
guidelines prioritized access to people who met the eligibility criterion of a CD4+ count threshold 
of <200 cells/µl or clinical criteria according to World Health Organization (WHO) stage 3 or 4. 
In adults, the national treatment guidelines recommended a 1st line regimen that included a weight 
based stavudine dosing (40 mg if weight above 60 kg, 30 mg if weight below 60kg), fixed dose 
lamivudine (150 mg 12 hourly) and efavirenz (600 mg at night) or nevirapine (200 mg daily for 
the 2 weeks, increasing to 200 mg twice daily). For 2nd line regimen, zidovudine (300 mg 12 
hourly), didanosine (400mg once daily, 250 mg once daily if weight below 60 kg) and ritonavir-
boosted lopinavir (400/100 mg 12 hourly).  
Although the WHO ART guidelines for resource-limited settings urged countries “to begin 
planning to move away from stavudine-containing regimens” in 2006, stavudine continued to be 
widely used in standardized first-line regimens in low- and middle-income countries as it had a 
low acquisition cost, was available in fixed dose combination formulations and did not require 
laboratory monitoring for toxicity.9 WHO then recommended reduced doses of stavudine 
following the findings of a systematic review that lower doses caused less toxicity without 
reducing efficacy.43 Programmatic delays allowed continuation of high dose stavudine in a few 
patients who were enrolled in the cross-sectional study described below.  
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ART access program in South Africa has designated ART clinics that are located in primary care 
clinics, secondary level hospitals or tertiary care clinic.  We recruited from two Cape Town ART 
clinics. The first clinic was based in Groote Schuur Hospital, a referral centre for ART access for 
patients diagnosed while in this hospital or patients referred from primary care clinics. The 
second clinic was based in Cross Roads Day Hospital, a primary care centre located in a township.  
Main prevalence study 
The Metabolic complications of HAART (McHAART) study is a cross sectional study, whose 
aim was to determine the prevalence of metabolic complications of ART. Ambulatory HIV-
infected patients on the South African National Department of Health 1st line ART regimen 
(stavudine or zidovudine, each with lamivudine, PLUS efavirenz or nevirapine), 2nd line ART 
regimen (zidovudine, didanosine, PLUS ritonavir-boosted lopinavir) and those not yet on ART 
(ART-naïve) were recruited by convenient sampling consecutively from a list at two Cape Town 
ART clinics between 2007 and 2009. Patients were excluded if they had a history of diabetes 
mellitus or impaired glucose tolerance (IGT), had been on ART for less than 6 months, had an 
active acute opportunistic infection, had severe diarrhea (>6 stools/d), had tuberculosis within 1 
month of starting treatment, had received glucocorticoid therapy within the past 6 months, or 
were pregnant or known to have renal failure. The Research Ethics Committee of the Faculty of 
Health Sciences of the University of Cape Town approved the study. Before participating in the 
study, procedures and risks were explained to the subjects, who gave written informed consent to 
participate in the study. Additional consent was obtained for storage of genetic samples and 
linkage with clinical data. 
In brief, after screening and enrolment, participants were given an appointment date, instructed to 
fast the night before the appointment, and record the last dose of ingesting, where applicable. On 
the study day, participants underwent an oral glucose tolerance test (OGTT). Blood was drawn at 
0 and 120 minutes after ingesting 75 g of glucose in 250 mL of water, and kept on ice until 
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centrifuged within 4 hours. Plasma for antiretroviral quantification was collected into 4mL 
lithium heparin tubes, kept on ice until centrifuged within 4 hours, and was aliquotted and 
promptly frozen at −20°C, then stored at -70°C until analysis at the end of recruitment in 2009. 
Plasma for antiretroviral drugs, fasting glucose, cholesterol, and triglyceride were quantified 
using the 0 minute OGTT samples. Finger-prick lactate was measured. Buffy coats were collected 
from EDTA tubes and stored in the -80 freezer until DNA extraction. 
Clinical assessments were done in all participants. A neurologist examined a subset of 
participants to determine neuropathy status. Some participants underwent dual energy X-ray 
absorptiometry (DEXA) scans to measure bone density and body fat percentage.   
Self reported adherence was determined using a validated standard 4-day adherence questionnaire 
administered by trained field workers. We reviewed medical records to determine duration on 
antiretroviral therapy and current CD4+ lymphocyte counts and viral load. Current CD4+ count 
was regarded as the count measured within 3 months of the study visit.   
Standard criteria for clinical and laboratory evaluations were used and described in the first three 
publications that arose from the cross sectional study.9,44,45 Preliminary analysis of OGTTs in 339 
participants showed 2% had diabetes and 24% had impaired fasting glucose or glucose 
tolerance.45 In multivariate analysis, efavirenz emerged as a risk factor for dysglycaemia –a novel 
finding requiring additional research. The prevalence of DSP was 49% in 598 participants and 
was significantly associated with stavudine use.44 We measured plasma stavudine concentrations 
during the OGTT in 47 participants. We used a population pharmacokinetic approach to estimate 
the stavudine area under the concentration time curve (AUC) and found no association between 




Departmental collaborations at the University of Cape Town (UCT) 
The cross-sectional study was collaboration between three divisions within the Department of 
Medicine at the University of Cape Town. These are: Division of Endocrinology and Diabetic 
Medicine, Division of Neurology, and the Division of Clinical Pharmacology. The Division of 
Endocrinology and Diabetic Medicine conducted the main prevalence study looking at the 
metabolic complications of ART.  The Division of Neurology conducted neurological assessment 
in selected patients. The Division of Clinical Pharmacology conducted the pharmacokinetics and 
pharmacogenetics sub-studies reported in this thesis and I (Phumla Zuleika Sinxadi), was the lead 
investigator on all. Of note, the pharmacology laboratory at the University of Cape Town is one 
of the AIDS Clinical Trial Group (ACTG) approved site, has world accreditation, and has 
conducted all the pharmacokinetics analyses reported in the studies included in this thesis. 
UCT –Vanderbilt University collaboration 
The pharmacogenomics components of this thesis were done in collaboration with Vanderbilt 
University School of Medicine, Nashville, Tennessee, United States of America. The studies done 
complied with the Helsinki Declaration and were approved by institutional review boards for 
each site. Only participants who gave separate consent for genetics storage and analyses were 
enrolled. Participants or their parents gave written consent or assent as appropriate.  
Clinical and laboratory (including pharmacokinetic analyses) data were collected in Cape Town.  
Genotyping and mitochondrial sequencing was done at Vanderbilt University. This minimal risk 
study used existing stored samples for DNA and pharmacokinetic analyses and clinical data from 
the McHAART study. In addition, pooled analyses with a paediatric study of African children on 
efavirenz based therapy and off tuberculosis therapy were enrolled for the study investigations 
genetic predictors of plasma efavirenz concentrations. We utilized stored DNA for genotyping 
and mitochondrial sequencing done at Vanderbilt University.  
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Our collaborators at Vanderbilt, with Todd Hulgan as the lead investigator, have identified 
associations between mtDNA haplogroups and ART related complications. My co-supervisor, 
David Haas, has led seminal that demonstrated that a frequent CYP2B6 variant (516G→T) 
predicted decreased plasma efavirenz clearance and increased plasma efavirenz concentrations. 
Professor Gary Maartens, my main supervisor, has conducted several studies in HIV and TB, and 
one of the key opinion leaders in the field.  
Chronology of the studies 
The chronology of the studies constituting this thesis is set out according to the publication date 
of the papers.  
Chapter 3 
Sinxadi PZ, McIlleron HM, Dave JA, Smith PJ, Levitt NS, Maartens G. Association of lopinavir 
concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a 
cross sectional study. AIDS Res Ther. 2012 Oct 26; 9(1): 32. doi: 10.1186/1742-6405-9-32. 
PubMed PMID: 23098156; PubMed Central PMCID: PMC3533776. 
The aim was to characterize associations between lopinavir plasma concentrations and the lipids 
and glucose concentrations.  
Chapter 4 
Sinxadi PZ, Dave JA, Samuels DC, Heckmann JM, Maartens G, Levitt NS, Wester CW, Haas 
DW, Hulgan T. Mitochondrial genomics and antiretroviral therapy-associated metabolic 
complications in HIV-infected Black South Africans: a pilot study. AIDS Res Hum Retroviruses. 
2013 Jul; 29(7):1031-9. doi: 10.1089/AID.2012.0373. Epub 2013 Mar 15. PubMed PMID: 
23428049; PubMed Central PMCID: PMC3685683. 
We explored associations between African mitochondrial DNA (mtDNA) haplogroups and ART-
associated lipoatrophy, dysglycaemia, hypertriglyceridaemia, and/or distal peripheral neuropathy 
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in Black HIV- infected South African population.  
Chapter 5 
Sinxadi PZ, Leger PD, McIlleron HM, Smith PJ, Dave JA, Levitt NS, Maartens G, Haas DW. 
Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South 
Africa. Br J Clin Pharmacol. 2015 Jul; 80(1):146-56. doi: 10.1111/bcp.12590. Epub 2015 May 
28. PubMed PMID: 25611810; PubMed Central PMCID: PMC4500334. 
The aim was to determine whether interindividual variability in plasma efavirenz concentrations 
is predicted by genetic polymorphisms in CYP2B6, alone or in combination with polymorphisms 
in additional relevant genes (CYP2A6, ABCB1, CYP3A4, CYP3A5 and PXR). We included adults 
and children who had been enrolled in two observational studies. In the adult study, adults from 
the public sector antiretroviral therapy (ART) program were enrolled in a cross sectional study to 
evaluate the associations between plasma efavirenz concentrations and metabolic complications.  
In the paediatric study, African children on efavirenz-based therapy with or without rifampicin-
based antituberculosis therapy were enrolled to evaluate the effect of rifampicin-based 
antituberculosis therapy on efavirenz concentrations.  The present analyses included only data 
from children who were not receiving rifampicin.  
Chapter 6. 
Sinxadi PZ, McIlleron HM, Dave JA, Smith PJ, Levitt NS, Haas DW, Maartens G. Plasma 
efavirenz concentrations are associated with lipid and glucose concentrations. Medicine (in 
press). 
The aim was to characterize associations between efavirenz plasma concentrations and the lipids 




Outline of the thesis 
In Chapter 2 (Background and literature review) literature review regarding the prevalence of the 
metabolic complications is presented. The data is divided into two parts, 1) data of the prevalence 
of ART related metabolic complications in high-income countries, 2) data of the prevalence of 
ART related metabolic complications in Sub-Saharan Africa, where the majority of the people 
living with HIV reside. Thereafter, more in-depth literature review on the four topics relevant to 
the studies presented in this thesis; data linking associations between the metabolic complications 
and efavirenz and lopinavir plasma concentrations; pharmacogenetics of efavirenz; and lastly, 
mitochondrial genomics and metabolic complications.  
In Chapter 3 the cross sectional study whose aim was to characterize associations between 
lopinavir plasma concentrations and lipid and glucose concentrations is reported. This lopinavir 
pharmacokinetic-pharmacodynamic study is included as a full manuscript with the introduction, 
methods, results and discussion and conclusions.  
In Chapter 4 a pilot study whose aim was to explore associations between African mitochondrial 
DNA haplogroups and metabolic complications (dyslipidaemia, dysglycaemia, hyperlactataemia, 
lipoatrophy and distal peripheral neuropathy) is reported. This mitochondrial genomics study is 
included as a full manuscript with the introduction, methods, results, discussion and conclusions.  
In Chapter 5 the pooled analyses whose aim was to determine whether interindividual variability 
in plasma efavirenz concentrations is predicted by genetic polymorphisms in CYP2B6, alone or in 
combination with polymorphisms in additional relevant genes (CYP2A6, ABCB1, CYP3A4, 
CYP3A5 and PXR) is reported. This efavirenz pharmacokinetics-pharmacogenetics study is 
included as a full manuscript with the introduction, methods, results, discussion and conclusions. 
In Chapter 6 the cross sectional study whose aim was to characterize associations between 
efavirenz plasma concentrations and lipid and glucose concentrations is reported. In a subset of 
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participants with available CYP2B6 genetic polymorphism data, associations between CYP2B6 
polymorphisms and lipids and glucose concentrations is explored. This efavirenz 
pharmacokinetic-pharmacodynamic-pharmacogenetics study is included as a submitted 
manuscript with the introduction, methods, results and discussion and conclusions.  
In Chapter 7 the findings of the four studies are summarized and conclusions from across all the 
studies are presented. The implications of the research for the field in general are discussed and 
priorities for future ART related complications are identified. 
Coherence of the thesis 
I (Phumla Zuleika Sinxadi) am the first author on all four papers included in this thesis, and was 
the lead investigator on all the studies. Professors Gary Maartens and David Haas jointly 
supervised the studies while I was registered as a student at the University of Cape Town, 
including when I visited Vanderbilt University as a non-degree seeking student. All four studies 
include participants recruited from the same cross-sectional study that investigated the prevalence 
of ART- associated metabolic complications. The body of work from all studies provide data that 
may improve understanding of the pathogenesis of ART-related complications among 
populations hardest hit by HIV by looking at genomic predictors of metabolic complications or 
drug concentrations, and the associations between drug concentrations and these metabolic 
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Background and literature review 
Sub-Saharan Africa carries the highest global burden of people living with HIV, with an 
estimated 26 million living in this region.1,2 Efforts to control the epidemic include up-scaling 
access to antiretroviral therapy (ART) in low to middle income countries.1 In 2014, 10.7 million 
people were accessing ART, with 5/7 people on ART living in Sub-Saharan Africa.1,2 Improved 
access to ART has led to an appreciable decline in the incidence of new HIV infections, as well 
as AIDS related deaths.1  
South Africa is home to more people living with HIV than any other country.3 In the 2012 
household survey, the HIV prevalence in South Africa was estimated at 12.2% (6.4 million 
persons), with the prevalence varying greatly by age, race, sex and province. Over 6,2 million 
black Africans were living with HIV, with the females in their 20s to early 30s being the worst 
affected.3 Of the 6,4 million people living with HIV in South Africa, only just over 2 million 
persons (31.2 %) were exposed to ART.3  
The UNAIDS 90-90-90 2020 goal is an ambitious treatment target that aims to end an AIDS 
epidemic. Their goals are to diagnose 90% of people living with HIV by 2020, treat 90% of 
people living with HIV by 2020, and to achieve 90% of viral suppression in people receiving 
ART.1 This ambitious treatment target aims to increase ART coverage by treating early after 
diagnosis irrespective of CD4+ count, which is projected to increase gains by averting infections, 
reducing morbidity and mortality. Therefore, people living with HIV will have longer duration of 
exposure to antiretroviral drugs, and will be susceptible to ART related complications, including 
metabolic complications, arising from cumulative exposure.  
In children aged ≥3 years and adults, the World Health Organization (WHO) recommends 
combination ART consisting of a nucleoside (nucleotide) reverse transcriptase inhibitor (NRTI) 
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backbone with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-
boosted protease inhibitor (PI) for first and second line regimens.4 
Prevalence of metabolic complications of ART 
Studies conducted in Europe, United States and Australia 
Antiretroviral drugs and dyslipidaemia 
The prevalence of metabolic complications is well studied in high-income countries. In 2003, the 
Data collection on Adverse events of anti-HIV Drugs (DAD study), a multinational, tri-
continental collaboration between established HIV cohorts with over 20000 participants reported 
that combination ART use was associated with an increased risk of myocardial infarction.5 The 
DAD study group also reported that risk factors for cardiovascular disease (myocardial infarction 
and stroke) were independently associated with PI-containing regimens or NNRTI-containing 
regimens, or regimens containing both PIs and NNRTIs.6 The risk of dyslipidaemia was strongly 
associated with the combined use of PIs and NNRTIs, suggesting additive effects.6 The DAD 
study group published several other studies including at study looking at individual drugs,7 which 
showed that ritonavir-containing regimens were associated with higher total cholesterol (TC) and 
triglycerides (TG) levels and total cholesterol: high density lipoprotein cholesterol (TC: HDL-c) 
ratios than were indinavir-containing regimens; however, receipt of nelfinavir was associated 
with reduced risk of lower HDL-c levels, and receipt of saquinavir was associated with lower 
TC:HDL-c ratios.7 Importantly, there is a small independent increased risk of MI in people on 
ART with high TG levels after adjusting for known confounders and TC and HDL cholesterol.8 
Patients receiving NNRTIs had higher levels of TC and LDL-c than did antiretroviral-naive 
patients, although the risk of having lower HDL-c levels was lower than that in patients receiving 
a single PI. Efavirenz was associated with higher levels of TC and TG than was nevirapine.7 The 
2NN study, a 48 week randomized controlled trial in ART-naïve patients randomized to efavirenz 
or nevirapine, also demonstrated that NNRTI containing regimens, especially nevirapine, were 
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associated with larger increases in HDL cholesterol and lower TC: HDL ratios. Therefore, PI-
sparing regimens based on NNRTIs, especially nevirapine, are expected to result in lower 
coronary heart disease risk.9  
It is important to note that describing causality of dyslipidaemia in a context of HIV is difficult.  
HIV infection itself can cause alterations in serum lipids.10,11 Typically, untreated patients with 
advanced disease evidenced by high viral load and longer duration of infection, will have low 
total-, LDL-, HDL-cholesterol and high triglyceride concentrations. This is thought to be a direct 
effect of the HIV infection.12 When starting ART, examining the baseline lipids and choosing the 
least atherogenic regimen in important.  
Antiretroviral drugs and insulin resistance or dysglycaemia 
Combination ART has also been associated with the increased incidence of new onset diabetes in 
HIV infected adults.13 The DAD study identified stavudine and zidovudine as the drugs 
associated with the highest incidence of new onset diabetes, and this was attributed to their ability 
to cause mitochondrial toxicity leading to insulin resistance.13 Insulin resistance in treated HIV is 
also associated with use of indinavir, full dose ritonavir (but not boosting doses), lopinavir, but 
not atazanavir.14 Studies in healthy volunteers report conflicting results regarding the association 
between lopinavir and insulin resistance.15,16 Even though efavirenz and nevirapine are not 
associated with decreased insulin sensitivity, marginal increases in fasting glucose have been 
associated with efavirenz use.14,17 The incidence of insulin resistance with or without 
hyperglycaemia is reportedly higher in treated HIV infected patients compared to the general 
population.18 Although the prevalence of insulin resistance in HIV is reported to range between 
35% and 47% with PI therapy, with the prevalence of hyperglycaemia ranging between 3-5% and 
diabetes occurring in only 1%,18 this cannot be regarded as a class effect.17 
Hyperglycaemia or insulin resistance forms part of the metabolic syndrome. The metabolic 
syndrome is a term used to describe the clustering of risk factors for cardiovascular disease, 
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including elevated TG, low HDL, hypertension, hyperglycaemia/ insulin resistance and intra-
abdominal obesity.19 In the DAD study group, at baseline, 2439/33347 (7.3%) individuals met the 
criteria for the metabolic syndrome.20 However, the prevalence has been reported to be as high as 
45%, depending on the criteria used for the definition.19 The association between metabolic 
syndrome and antiretroviral therapy is unclear, as individual drugs contribute to its components. 
For example, first generation protease inhibitors are known to cause high TG, whereas efavirenz 
and nevirapine increase LDL as well as HDL.19 However, there is an increase in prevalence of the 
metabolic syndrome with prolonged therapy. Of importance, other risk factors such as age, sex, 
smoking should be taken into account when risk assessment is performed in HIV infected 
patients.19 
Antiretroviral drugs and altered fat body distribution 
Altered fat distribution (loss of subcutaneous fat and a relative increase in central fat) is another 
important complication seen in patients on long term ART.21 The prevalence rates vary widely, 
11-83%, in cross-sectional studies, and increasing rates are thought to be related to NRTI and PI 
use.21 A systematic review concluded that there is a causal relationship between NRTIs 
(especially thymidine analogues) and lipoatrophy, with efavirenz causing an additive effect.22 By 
contrast, central fat gain appears to be a consequence of treating HIV infection, because it does 
not differ between those treated with ART and controls, is not linked to any antiretroviral class, 
and doesn't improve on switching.22 An observational study reported that altered fat distribution 
(lipoatrophy alone, fat gain alone, or mixed lipodystrophy phenotypes) is significantly associated 
with an increase cardiovascular risk.23 
Antiretroviral drugs and hyperlactataemia 
One of the important ART related complications that has impacted the way we prescribe ART is a 
rise in serum lactate, with or without acidosis.24 Hyperlactataemia, associated with use of 
nucleoside analogue reverse transcriptase inhibitors (NRTIs), is not a single entity but a spectrum 
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of abnormalities.25 The presentation varies from the common asymptomatic or symptomatic 
hyperlactataemia to a rare lactic acidosis, which has a high mortality.25 In addition to other 
complications attributed to NRTI use, such as lipoatrophy, peripheral neuropathy and other 
metabolic abnormalities, the World Health Organization has since advocated for the 
discontinuation of use of stavudine and didanosine.4 Where stavudine continues to be used, a 
reduction of dose has been advocated as improvement in metabolic parameters, such as lipids has 
been demonstrated.26 However, a recently published Cochrane systematic review has not 
identified a clear efficacy or safety advantage of stavudine dose reduction.27        
Antiretroviral drugs and peripheral neuropathy 
Distal sensory polyneuropathy (DSP), including both antiretroviral toxic neuropathy and primary 
HIV sensory neuropathy, is one of the most common neurologic complications of HIV 
infection.28 DSP causes pain and diminished exercise tolerance, resulting in reduced quality of 
life, disability and often requiring chronic analgesic use. Studies performed during the era prior to 
ART showed that the risk and severity of DSP was associated with advancing 
immunosuppression (lower CD4 cell count) and increased plasma HIV viral load.29 However, 
despite improvements in immune function and viral suppression with ART, DSP remains 
common.28 Although certain components of ART, specifically dideoxynucleoside drugs 
(stavudine and didanosine: “d-drugs”) may account for persisting DSP in some, the use of these 
drugs has declined, suggesting that stavudine or didanosine associated neuropathy cannot fully 
explain the increasing numbers of individuals experiencing DSP. The pathogenesis of “d-drug” 
associated neuropathy is thought to be the inhibition of DNA polymerase gamma, with 
subsequent mitochondrial DNA depletion.30 PIs have not been shown to be associated with an 
increased risk of DSP.28 Other risk factors, such as substance abuse, genetic predisposition, low 




These data reviewed above are from high-income countries and may not be generalizable to the 
Sub-Saharan population, which carries the highest burden of disease. For example, the DAD 
study cohort consisted of 24% female, median age 39, median CD4 count 430, 6% black, 24% 
heterosexual HIV acquisition. The protease inhibitors used at the time were nelfinavir, saquinavir, 
indinavir, which are no longer recommended due to poor efficacy or high toxicity. At the time 
ART was made available to South Africa, saquinavir, nelfinavir and indinavir were no longer the 
protease inhibitors of choice for the management of HIV infection and the demographics of most 
study populations differ. In Sub-Saharan region, the majority of patients included in the studies 
are younger black women with relatively lower CD4 counts at baseline, whereas, the cohorts 
from the Europe, Australia and United States consists mainly of white men. With this in mind, it 
is essential to highlight the data from the Sub-Saharan region, where the majority of the people 
living with HIV reside.  
Studies conducted in Sub-Saharan region 
The International Database to Evaluate AIDS (IeDEA) described temporal trends in baseline 
characteristics, initial regimens and monitoring of patients starting ART in resource-limited 
settings.35 They analyzed data from 17 cohorts including 12 countries in sub-Saharan Africa, 
South America and Asia, between 1996-2006. In line with the WHO guidelines at the time, the 
majority of patients living in sub-Saharan Africa were started on ART consisting of stavudine, 
lamivudine and nevirapine and the median baseline CD4 count was below 200cells/µL (lowest in 
2002 median 60 cells/µL and it increased to median of 122 cells/µL). In this region, nearly two 
thirds were younger females with a median age of 35 years at ART initiation.35 Initially, one of 
the challenges faced by the antiretroviral access programs in sub-Saharan Africa was high early 
mortality (up to 26% in the first year of ART, with most death occurring in the first few months) 
observed in adults accessing treatment.36 During this era, patients typically accessed treatment 
with advanced symptomatic disease, and mortality was strongly associated with baseline CD4 
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count less than 50 cells/µL and WHO stage 4 disease (AIDS).36 With early diagnosis and 
improved access to earlier treatment, the morbidity and mortality in sub-Saharan Africa has also 
improved, with the AIDS related deaths reported to have declined by 48% between 2004 and 
2014.2  
With the improved longevity with ART, cumulative exposure has been associated with toxicity. 
The African Partnership for Chronic Disease Research study group, which published a systematic 
review and meta-analysis from 49 published and 3 unpublished studies, included data from 29755 
adult Black individuals (5586 with individual level data) who were either HIV infected (on ART 
or untreated) or HIV uninfected from 14 trial sites sub-Saharan region.37 They reported that HIV 
infection was associated with higher TG concentrations in univariate analyses, or after adjusting 
for data clustering, ART exposure, age, sex, body mass index (BMI), education level, and 
smoking status.37 HIV infection was associated with lower systolic and diastolic blood pressure. 
Interestingly, in the HIV infected individuals, ART use was associated with lower TG 
concentrations and lower HbA1c. In multivariate analyses adjusting for data clustering, age, sex, 
body mass index (BMI), education level, and smoking status, ART was associated with higher 
LDL and HDL cholesterol.37 The authors couldn't delineate the risk to individual ART drugs or 
drug class, but speculate that some of these findings differ from DAD study findings, which 
showed that ART is associated with higher TG concentrations, because there were fewer 
individuals on protease inhibitors in this meta-analysis.37  
Access to antiretroviral drugs in certain parts of South Africa was made possible by non-
governmental organizations prior to the rapid access antiretroviral rollout by the National 
Department of Health of South Africa in 2004. In line with the WHO recommendations at the 
time, only two treatment regimens were recommended: an initial NNRTI based regimen, 
followed by a PI-based regimen. Until April 2010, the first-line regimen in South Africa consisted 
of stavudine, lamivudine and nevirapine or efavirenz. The second-line regimen consisted of 
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zidovudine, didanosine and ritonavir-boosted lopinavir. Even though the majority of patients 
tolerated their first-line regimen well, twenty eight percent of patients had substitution in the first 
3 years.38 The cumulative incidence of stavudine associated grade 3 or 4 toxicities (peripheral 
neuropathy, symptomatic hyperlactataemia, and lipodystrophy) increased over time, with 21% of 
individuals stopping stavudine within 3 years because of toxicity.38 Other reasons for 
substitutions in this study were related to zidovudine related haematological toxicity, NNRTI 
hypersensitivity and contraindications related to newly diagnosed tuberculosis and potential drug-
drug interactions.38 As stavudine is being currently phased out as recommended, by WHO, the 
currently recommended first line regimen consists of tenofovir, emtricitabine and efavirenz,4 with 
the second line treatment that consist of zidovudine, lamivudine and ritonavir-boosted lopinavir. 
Efavirenz is extensively prescribed and is included in the World Health Organization’s preferred 
first-line ART regimens for HIV-1 infected adults, adolescents and children at least 3 years of 
age.4 Efavirenz-based ART has been associated with the development of dyslipidaemia;7,39,40 
specifically increases in total cholesterol: HDL cholesterol ratio, LDL cholesterol, and 
triglycerides.9,41 The prevalence rates of dysglycaemia were found to be similarly high in the 
ART naïve and treated South African patients.42 High prevalence of both dyslipidaemia and 
dysglycaemia has been reported from other African countries.43-45 However, within the treated 
HIV patients, the prevalence of dysglycaemia almost tripled in the group that was treated with the 
efavirenz-based first line regimen compared with nevirapine-based first line regimen.42 
NRTI-related mitochondrial toxicity attributed to the inhibition of mitochondrial DNA 
polymerase gamma and subsequent mitochondrial dysfunction by “d-drugs”, has been described 
as the molecular mechanism of many of these metabolic effects (lipoatrophy, hyperlactactaemia, 
peripheral neuropathy, dyslipidaemia and insulin resistance).46-48 In addition, the acute inhibition 
of the glucose transporter GLUT4 by first generation PIs at therapeutic concentrations is also well 
characterized.49 However, understanding these complications is challenging. For example, it is 
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known that the development of adverse events is not a class effect, but these adverse events are 
associated with the individual drugs.50 Several studies have investigated the pharmacokinetic-
pharmacodynamics relationships of ART associated adverse events, or genetic predisposition and 
the development of the ART associated adverse events. These are discussed below.  
PHARMACOKINETIC-PHARMACODYNAMIC ASSOCIATIONS OF ART-
ASSOCIATED METABOLIC ADVERSE EVENTS 
Even though the association between antiretroviral drugs and metabolic adverse events is well 
described, there is paucity of data linking the adverse events to antiretroviral drug concentrations. 
Therapeutic drug monitoring (TDM) was proposed to optimize response to ART, improve 
virologic suppression, and minimize toxicity. However, some antiretroviral drugs, such as NRTIs, 
are unsuitable for TDM due to the poor correlation between the plasma concentrations and the 
active intracellular phosphorylated anabolites. A systematic review that identified 8 randomized 
controlled trials found no evidence to support routine TDM in all patients on either boosted PI or 
NNRTIs.51 The authors concluded that TDM might be of value in patients on unboosted PIs.51 
This section will focus on the literature review on the association between efavirenz and lopinavir 
and metabolic complications.  
Efavirenz concentrations and metabolic complications 
Efavirenz-based ART has been associated with the development of dysglycaemia42 and 
dyslipidaemia;7,39,40 specifically increases in total cholesterol: HDL cholesterol ratio, LDL 
cholesterol, and triglycerides.9,41 The pathogenesis of these metabolic effects are unclear, 
although it has been suggested that efavirenz may contribute to mitochondrial toxicity caused by 
concomitant thymidine analogue nucleoside reverse transcriptase inhibitors (NRTI).47 There is 
contradictory, albeit limited, data regarding the association of efavirenz plasma concentrations 
with lipids and glucose (Table 1).52-55  
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There is considerable interindividual variability in plasma efavirenz exposure, which is largely 
explained by three CYP2B6 loss-of-function polymorphisms.56,57 The two polymorphisms with 
the greatest effect, CYP2B6 516G→T and CYP2B6 983T→C, are particularly frequent with 
African ancestry.58,59 This, in part, explains why efavirenz levels concentrations are higher in 
patients of African ancestry.56   
In vitro studies have demonstrated that efavirenz toxicity may be attributed to concentration 
dependent mitochondrial toxicity, a mechanism independent of polymerase gamma inhibition.60-62 
With the reported associations between efavirenz and dyslipidaemia and dysglycaemia, we 
hypothesized that, in a populations where a high proportion of patients are likely to have high 
concentrations, higher plasma efavirenz concentrations would be associated with higher lipid and 
glucose concentrations. We investigated whether plasma efavirenz concentrations correlated with 
plasma lipid and/or glucose concentrations in HIV-infected South Africans. We also explored if 
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Lopinavir concentrations and metabolic complications 
Ritonavir boosted lopinavir (LPV/r) is a potent protease inhibitor (PI) widely used in a second-
line antiretroviral regimens in low and middle-income countries.4 Treatment with LPV/r has been 
associated with the development of dyslipidaemia, which is a known risk factor for 
cardiovascular complications.13,63 A systematic review including 15 trials and 6367 participants 
showed that ritonavir-boosted lopinavir had a similar effect on total cholesterol when compared 
with efavirenz.64 However, triglycerides were higher in the ritonavir-boosted PI arms compared 
with efavirenz.64  
There are conflicting results regarding an association between LPV/r use and the development of 
insulin resistance and new onset diabetes. 16,47,65-67 Furthermore, there is contradictory data as to 
whether the metabolic toxicity is associated with higher plasma concentrations of either lopinavir 
or ritonavir.54,68-71  Table 2 illustrates the different studies that have investigated the association 
between the lopinavir or ritonavir concentrations and metabolic parameters. 
Lopinavir is metabolized primarily by hepatic cytochrome P450 (CYP) 3A isoforms and is a 
substrate for p-glycoprotein (P-gp).72 Its co-formulation with ritonavir increases lopinavir 
exposure by inhibiting intestinal and hepatic CYP3A-mediated and P-gp-mediated drug 
metabolism and transport, respectively.72 Recently, protease inhibitors have been reported to be 
substrates of the drug transporter belonging to the organic anion transporting polypeptide 
(OATP/SLCO) family.72 Lopinavir has large interindividual PK variability, at least part of which 
can be explained by age, sex, body weight, drug-drug interactions, liver disease, pregnancy and 
poor-adherence.72 The remaining variability is attributed to host genetic factors.  
Limited studies have found no association between LPV plasma concentrations and 
polymorphisms in ABCB1, CYP3A5, CYP2B6 and CYP2D6 genes.73 However, in HIV infected 
men, recent studies have reported “gain of function” (rs11045819) and “loss of function” 
(rs4149056) variants in SLCO1B1 gene, which may lead to low and high plasma concentrations 
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of LPV, respectively.72,73 In our population, where the prevalence of HIV and tuberculosis co-
infection is high, concomitant administration of lopinavir and rifampin based antituberculous 
therapy is common. Furthermore, a recent study found an association between an SLCO1B1 
variant (rs4149032), a highly prevalent polymorphism, and low rifampicin exposure.74  
Widespread long-term PI use may be limited by these metabolic complications. We investigated 
whether plasma lopinavir concentrations correlated with plasma lipid and/or glucose 
concentrations in HIV-infected South Africans. As lopinavir has a high interindividual variability, 
which may be explained by genetic polymorphisms,72,73,75,76 we hypothesized higher plasma 
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PHARMACOGENOMICS OF ANTIRETROVIRAL DRUGS 
Genetic polymorphisms have been associated with interindividual variability of antiretroviral 
drug disposition, ART related toxicities and ageing related complications of HIV.  Therefore, 
pharmacogenomics may identify patients at increased risk for toxicity and/or reduced efficacy of 
antiretroviral therapy. This review will focus on the pharmacogenomics efavirenz and 
mitochondrial genomics of NRTI associated metabolic complications.  
Efavirenz pharmacogenomics 
Efavirenz is metabolized primarily by cytochrome P450 (CYP) 2B6.80 The metabolic pathway of 
efavirenz is displayed in Figure 1.81 Efavirenz is extensively prescribed for HIV-1 infection 
worldwide. While generally safe and effective, some efavirenz recipients experience virologic 
failure,82 and/or central nervous system symptoms.83 There is considerable interindividual 
variability in plasma efavirenz exposure, which is largely explained by CYP2B6 loss-of-function 
polymorphisms.56,57 Analyses with AIDS Clinical Trials Group (ACTG) protocol 5097s first 
showed that the non-synonymous polymorphism CYP2B6 516G→T (rs3745274) was strongly 
associated with increased plasma efavirenz exposure.56 Many studies have since replicated this 
association.84-87 The CYP2B6 516 T allele is more frequent with African ancestry than with 
European ancestry,58 which largely explains the greater mean plasma efavirenz concentrations 
reported among populations of African descent.88,89 The CYP2B6 516G→T polymorphism is also 
frequent in Thai and Cambodian populations.90,91A considerably less frequent CYP2B6 
polymorphism, 983T→C (rs28399499), also predicts increased plasma efavirenz exposure.92-94 
The CYP2B6 983 C allele is found almost exclusively with African ancestry, among whom it is 
still much less frequent than 516G→T.95 Therefore, the two polymorphisms with the greatest 




Additional CYP2B6 polymorphisms suggested to affect CYP2B6 activity have been extremely 
infrequent,92,96,97 or have not predicted plasma efavirenz exposure.97,98 Polymorphisms in genes 
beyond CYP2B6 reported to affect interindividual variability in efavirenz pharmacokinetics 
include CYP2A6,99 CYP3A5,56 UGT2B7,100 and CAR,101 although such associations have yet to be 
replicated. However, in a recent genome-wide associations study involving White, Black, and 
Hispanic adults in the United States, only CYP2B6 516G→T, 983T→C, and an intronic CYP2B6 
variant (rs4803419) were independently associated with estimated efavirenz trough 
concentrations (P=4.4x10-15).57  
Previous studies from Africa have replicated the association between CYP2B6 516G→T and 
plasma efavirenz exposure, including studies of patients from Zimbabwe 102-104, South Africa 105-
108, Ghana 109,110, Uganda 104,111, Tanzania 112,113, Rwanda 114, and Ethiopia 112. Multiple studies of 
patients from Africa have also shown the association with 983T→C 59,103,104,108,110,114. Data for 
association beyond CYP2B6 are limited. A study of patients in Ghana found associations with 
CYP2A6 and UGT2B7 polymorphisms 109, but a subsequent study of patients in Ghana did not 
replicate independent associations with these polymorphisms 110. 
We characterized relationships between candidate genetic polymorphisms and plasma efavirenz 





Figure 1. Efavirenz metabolic pathway. The metabolic pathway of efavirenz showing various 
genes involved in the efavirenz disposition. The star represents significant. The blue oval circles 
represent generic genes, greyish oval circle represents downstream target gene, purple rectangle 
represent the drug. Mixed purple and yellow rectangle represents metabolite. The main metabolite 
is 8-hydroxyefavirenz. CYP2B6= gene coding for cytochrome P450 isoenzyme 2B6. UGT= 
UDP-glucuronosyltransferase, transcription factors pregnane X receptor (PXR, NR1I2 ) and 
constitutive androstane receptor (CAR, NR1I3 ), NR1I2/NR1I3= gene coding for nuclear receptor 
subfamily 1, group I member 2/3 (reproduced by permission from the PharmGKB and Stanford 
University (url: https://www.pharmgkb.org/pathway/PA166123135) 
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Mitochondrial haplogroups and metabolic complications and peripheral neuropathy 
Exposure to ART has been associated with metabolic adverse effects such as dyslipidaemia, 
insulin resistance, dysglycaemia, central fat accumulation, peripheral fat loss (lipoatrophy), and 
peripheral neuropathy.30,48 Many of these adverse effects are thought to be related to NRTI-
related mitochondrial toxicity, at least in part due to inhibition of mitochondrial DNA (mtDNA) 
gamma polymerase and subsequent mitochondrial dysfunction.30 Other antiretroviral classes have 
also been associated with mitochondrial dysfunction.46,115  
Mitochondrial DNA is distinct from nuclear DNA and codes for 13 polypeptides essential for 
oxidative phosphorylation.116 Mitochondrial DNA exhibits abundant genetic variation across the 
16.6 kb mitochondrial genome. Human mtDNA sequences have diverged over approximately the 
last 150,000 years due to natural selection and human migration, resulting in distinct patterns of 
single nucleotide polymorphisms (SNPs), called haplogroups.117 Figure 2 shows the simplified 
phylogenetic tree (www.phylotree.org).118  
 
Figure 2. Simplified mtDNA phylogeny illustrating the use of alphabetical letters for 
haplogroup designation. A star representing the most recent common matrilineal ancestor of all 
humans indicates the root of the tree. The L haplogroups are the most deep-rooting lineages and 
are African specific indicating the African origin of modern humans. Haplogroup L3 gave rise to 
macrohaplogroups M, N and R, which encompass all variation observed outside Africa.   
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Studies in HIV-uninfected populations (primarily European and Asian) have reported associations 
between mtDNA and metabolic complications including dyslipidaemia and diabetes.119-123 A 
recent systematic review summarized studies of significant associations between mitochondrial 
haplogroups with HIV and /or ART-related complications potentially having mitochondrial 
mechanisms.124 Evidence for significant associations between European mtDNA haplogroups and 
outcomes in HIV infected participants has been reported for CD4 count recovery,125 AIDS 
progression,126 and ART related complications (including lipoatrophy,127-130 insulin 
resistance,131,132 dyslipidaemia,128 atherogenic risk,131 peripheral neuropathy,31,133,134 hepatic 
fibrosis/cirrhosis,135 and neuroretinal disorders136).  
  
The majority of HIV-infected persons worldwide reside in sub-Saharan Africa,1 but this region 
has been under-represented in genetic studies. Studies in African Americans showed conflicting 
results regarding associations between African mtDNA sub-haplogroup L1c and peripheral 
neuropathy,137,138 and a positive association between haplogroup L2 and CD4+ T-cell 
recovery.125,139 A study conducted in Malawi found that the African mtDNA subhaplogroup L02a 
increased the susceptibility to peripheral neuropathy, whereas subhaplogroup L2a was protective. 
At the time of conducting our study, there were no published studies that investigated 
associations between African mtDNA haplogroups and important metabolic complications 
including lipoatrophy, dysglycaemia or dyslipidaemia. Subsequently, a small study (n=37) 
conducted in South Africans showed no association between the African mtDNA haplogroups 
and hyperlactataemia.140 An updated table of studies including HIV-infected patients of African 
ancestry is summarized in Table 3. The discrepancy with different associations might be 
attributed to different mtDNA haplogroup frequencies found in different study populations. For 
example, in African Americans the frequent haplogroups are L1, L2, L3 (increasing order),141 and 
in the Malawians, the frequent haplogroups were L1, L3, L2 and L0 (increasing order).142  
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In this study, we report the prevalence of mtDNA haplogroups in a South African population 
enrolled in an ART program, and explore associations between African mtDNA and ART-
associated complications including metabolic complications and distal sensory polyneuropathy 
(DSP). Because ART-associated adverse effects in HIV-infected persons, and metabolic diseases 
in general, are believed to result in part from mitochondrial dysfunction, we hypothesized that 
mtDNA variation would be associated with susceptibility to ART-associated lipoatrophy, 
dysglycaemia, hypertriglyceridaemia and/or distal peripheral neuropathy in this South Africa. 
 
Table 3. Studies investigating associations between African mitochondrial DNA 
haplogroups and ART related complications. 
  African mitochondrial DNA haplogroup 
Study Phenotype L0 L1 L2 L3 
Canter137* Peripheral 
neuropathy 
 (L1c) ↑   
Holzinger138* Peripheral 
neuropathy 
 (L1c)↓   
Kampira142# Peripheral 
neuropathy 
(L0a2)↑  (L2a)↓  
Aissani139* CD4+ cell 
recovery 
  ↓  
Grady125* CD4+ cell 
recovery 
  ↓  
Hulgan143* CD4+ cell 
recovery 
  ↓  
Hulgan141* Neurocognitive 
impairment 
 ⇔ ⇔ ⇔ 
Arenas-
Pinto140$ 
Hyperlactataemia ⇔  ⇔ ⇔ 
*Studies conducted in African-Americans, # study conducted in Malawians, $study conducted in 
South Africans. Unless specified, the arrow showing the direction of the association refers to the 
major haplogroup. ↑ means increased risk, ↓ means protective effect, ⇔ means no associations 
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Abstract
Background: Dyslipidaemia and dysglycaemia have been associated with exposure to ritonavir-boosted protease
inhibitors. Lopinavir/ritonavir, the most commonly used protease inhibitor in resource-limited settings, often causes
dyslipidaemia. There are contradictory data regarding the association between lopinavir concentrations and
changes in lipids.
Aim: To investigate associations between plasma lopinavir concentrations and lipid and glucose concentrations in
HIV-infected South African adults.
Methods: Participants stable on lopinavir-based antiretroviral therapy were enrolled into a cross-sectional study.
After an overnight fast, total cholesterol, triglycerides, and lopinavir concentrations were measured and an oral
glucose tolerance test was performed. Regression analyses were used to determine associations between plasma
lopinavir concentrations and fasting and 2 hour plasma glucose, fasting cholesterol, and triglycerides
concentrations.
Results: There were 84 participants (72 women) with a median age of 36 years. The median blood pressure, body
mass index and waist: hip ratio were 108/72 mmHg, 26 kg/m2 and 0.89 respectively. The median CD4 count was
478 cells/mm3. Median duration on lopinavir was 18.5 months. The median (interquartile range) lopinavir
concentration was 8.0 (5.2 to 12.8) μg/mL. Regression analyses showed no significant association between
lopinavir pre-dose concentrations and fasting cholesterol (β-coefficient −0.04 (95% CI −0.07 to 0.00)), triglycerides
(β-coefficient −0.01 (95% CI −0.04 to 0.02)), fasting glucose (β-coefficient −0.01 (95% CI −0.04 to 0.02)), or 2-hour
glucose concentrations (β-coefficient −0.02 (95% CI −0.09 to 0.06)). Lopinavir concentrations above the median
were not associated with presence of dyslipidaemia or dysglycaemia.
Conclusions: There was no association between lopinavir plasma concentrations and plasma lipid and glucose
concentrations.
Keywords: Lopinavir, Hypercholesterolaemia, Hypertriglyceridaemia, Impaired glucose metabolism, Antiretroviral
therapy, Pharmacokinetics
Introduction
Ritonavir-boosted lopinavir (LPV/r) is a potent protease
inhibitor (PI) widely used in a second-line antiretroviral
regimens in low and middle-income countries [1]. Treat-
ment with LPV/r has been associated with the develop-
ment of dyslipidaemia [2,3], which is a known risk factor
for cardiovascular complications. The Women’s Intera-
gency HIV study showed that dyslipidaemia was more
severe in HIV infected women on ritonavir-boosted PI
containing antiretroviral therapy (ART), compared with
untreated HIV infected women or non-PI based ART
[4]. There are conflicting results regarding an association
between LPV/r use and the development of insulin re-
sistance and new onset diabetes [5-9]. Furthermore,
there are contradictory data as to whether the metabolic
toxicity is associated with higher plasma concentrations
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of either lopinavir or ritonavir [10-12]. Widespread long-
term PI use may be limited by these metabolic complica-
tions. Data regarding an association between plasma
lopinavir and plasma glucose concentration are lacking.
The aim of our study was to investigate whether there
is an association between plasma lopinavir and plasma
lipids and glucose concentrations. We hypothesized that
higher plasma lopinavir concentrations would be asso-
ciated with higher prevalence of dyslipidaemia and
dysglycaemia.
Materials and methods
Study design and participants
We conducted a prospective cross sectional study be-
tween February 2007 and January 2008. Consecutive am-
bulatory HIV infected African adults who presented for a
routine follow up visit at primary and tertiary level clinics
in Cape Town were recruited. Participants were eligible if
they were on lopinavir-based therapy for a minimum of
six months. Participants with renal or hepatic disease,
active opportunistic infection, diabetes, history of dia-
betes or dyslipidaemia and self-reported non-adherence
were excluded. The study was approved by the University
of Cape Town research ethics committee.
Clinical and laboratory evaluations
After obtaining informed consent, we instructed the par-
ticipants to undergo an overnight fast and to note the
time of taking the evening dose of lopinavir on the day
proceeding the study day. On the study day, participants
underwent an oral glucose tolerance tests (OGTT).
Blood was drawn at 0 and 120 minutes after ingestion of
75g glucose in 250ml water, into heparinised or sodium
fluoride tubes as appropriate, and kept on ice until cen-
trifugation within 4 hours. Plasma lopinavir concentra-
tions and serum fasting glucose, cholesterol, and
triglyceride concentrations were determined from the 0
minute samples of the OGTT. The morning doses of
ART were given after 2 hour glucose samples were taken.
Lopinavir drug concentrations were analyzed by fully
validated methods using liquid chromatography-tandem
mass spectrometry (LC-MS/MS) on an Applied Biosys-
tems MDS Sciex API 4000 tandem mass spectrometer at
our ISO17025 compliant and accredited analytical labora-
tory as previously described [13]. The assay range was
0.05 to 20 μg/mL. Accuracy ranged from 94 to 103%.
Any samples with lopinavir concentrations below the
limit of quantification (0.05 μg/mL) were fixed to 0.025
μg/mL. Serum glucose and lipid concentrations were
determined by standard methods using the ACE Alera
Clinical Chemistry System (Alfa Wassermann Diagnostic
Technologies, Woerden, Netherlands). Impaired fasting
glucose (IFG) and impaired glucose tolerance (IGT) were
defined according to the American Diabetes Association
criteria [14]. Hypercholesterolaemia and hypertriglyceri-
daemia were defined according to the NCEP III criteria [15].
We reviewed medical records to determine duration
on antiretroviral therapy, viral load and CD4 counts. Self
reported adherence was determined using a validated 4-
day adherence questionnaire administered by trained
field workers [16]. Basic anthropometric measurements
were measured by a biokineticist.
Pharmacokinetic and statistical analysis
The plasma lopinavir concentrations were obtained from
0 minute of the OGTT. For data points below the limit
of quantification (0.05 μg/mL), the lopinavir concentra-
tions were fixed to 0.025 μg/mL. The associations be-
tween lopinavir concentrations and glucose, triglycerides,
and cholesterol were determined using univariate linear
regression and multivariate analyses. Logistic regression
was used to determine associations between lopinavir




A previous study found a positive correlation (rho) of
0.32 between lopinavir trough levels and triglyceride
levels [10]. When the sample size is 50, the linear regres-
sion test of rho=0 (alpha= 0.050 two-sided) for normally
distributed triglyceride concentrations, will have 80%
power to detect a rho of 0.375.
Results
Of 93 participants enrolled for the study, nine were
excluded due to missing anthropometric and metabolic
data or inaccurate dose-sampling time. The baseline
characteristics of the 84 participants included in the ana-
lysis are in Table 1. The majority were women, reflecting
the epidemic seen in our clinical practice. All partici-
pants reported 100% adherence. The prevalence of
hypercholesterolaemia, hypertriglyceridaemia, impaired
fasting glucose, impaired glucose tolerance, and diabetes
were 29%, 29%, 25%, 14% and 4% respectively. The
plasma LPV concentrations are shown in Figure 1. The
median (IQR) time after dose was 13.2 (12.6 to 14.1)
hours. There were ten participants whose lopinavir con-
centrations were below 1 μg/mL (12%). Of these, 4 were
virologically suppressed, 4 had virologic failure, and 2
had missing viral load data. As there was a significant
association between time after dose and lopinavir con-
centrations, the time after dose was included in the
multivariate regression analyses investigating the associ-
ation between lopinavir concentrations and metabolic
parameters. There were no significant associations be-
tween lopinavir concentrations and lipid and glucose
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concentrations on simple regression analyses, or after
adjusting for age, sex, time after dose, and duration on
lopinavir (Table 2). The lack of association between lopi-
navir concentrations and the metabolic parameters per-
sisted when the 10 participants with lopinavir
concentrations below 1 μg/mL (as they were probably
non-adherent) were excluded (data not shown). Sixty
one percent of participants were on zidovudine and di-
danosine combination (Table 1), as recommended by the
South African antiretroviral guidelines at the time. How-
ever, the different NRTI backbone was not associated
with any of the outcomes evaluated. For example, for tri-
glycerides, in the participants of the same age, sex,
duration on lopinavir, and with same lopinavir concen-
tration taken at the same time after dose, there was no
significant difference between those who were on zi-
dovudine/didanosine combination compared to other
NRTI combinations [mean difference −0.22(−0.65 to
0.21) mmol/L, p value =0.31]. Similarly, there was no as-
sociation with NRTI backbone and cholesterol if there
all parameters remained the same [mean difference
−0.18(−0.73 to 0.37) mmol/L, p value =0.51]. There was
no association between lopinavir concentrations above
the median (8 μg/mL) and dyslipidaemia or dysglycae-
mia (see Figure 2).
Discussion
To our knowledge, this is the first study to investigate
the association between lopinavir concentrations and
serum glucose concentrations, and the first to investigate
associations between lopinavir concentrations and serum
lipids in a South African population. Despite a high
prevalence of dyslipidaemia (29%) and dysglycaemia (42%)
in 84 black South African HIV-infected adults treated with
ritonavir-boosted lopinavir for a median duration of
19 months, we found no association between plasma lopi-
navir concentrations and lipid or glucose concentrations.
There was also no significant association between the lopi-
navir concentrations above the median, and hypercholes-
terolaemia, hypertriglyceridaemia or dysglycaemia.
We found the median lopinavir concentration was 8
μg/mL, which is higher than reported elsewhere [17,18],
but comparable to the trough concentrations after
observed doses in a study conducted by our group from
the same community [19]. Lopinavir pharmacokinetics
Table 1 Study population characteristics, N=84
Variable Median (IQR)
or n/N(%)
Age (years) 36 (32–42)
Female n/N (%) 72/84 (86)
Race n/N (%)
Black 84/84 (100)
Weight (kg) 69 (60–82)
Body mass index (kg/m2) 26 (23–32)
Waist: hip ratio 0.88 (0.82-0.94)





Blood pressure mmHg 108/72 (102/66-119/77)




Proportion with <400 copies/mL (%)* 64/74 (86)
Duration on lopinavir (months) 19 (9–29)







Fasting cholesterol 4.3 (3.7 to 5.3)
Fasting triglycerides 1.3 (0.9 to 1.8)
Fasting glucose 5.2 (4.7 to 5.7)
2 hour glucose 6.3 (5.4 to 8.1)
* 10 participants had missing current viral load data.
Figure 1 Scatter plot of lopinavir concentrations (μg/mL) and
the time after the last lopinavir dose (hours). The black dots
denote individual lopinavir concentrations plotted against the time
after the last unobserved lopinavir dose (dose to sampling time)
from 84 participants. The regression line shows negative correlation
between the lopinavir concentrations and the dose to sampling
time (Spearman rho (95%CI)= −0.28(−0.47 to −0.06), p-value 0.01).
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demonstrate considerable interindividual variability,
which may affect treatment outcomes. At least part of
this variability may be explained by host genetic factors.
Associations between human genetic variants and lopi-
navir exposure are incompletely understood and need to
be explored.
The lack of an association between lopinavir concen-
trations and lipid or glucose concentrations that we
found can be explained as follows: First, like all prote-
ase inhibitors, lopinavir exerts its antiviral activity
intracellularly, and the plasma and intracellular half-lives
are different [20]. However, the positive correlation
between lopinavir plasma and intracellular concentra-
tions reported at 4 weeks was not sustained at 24
weeks of treatment [20]. More importantly, the mech-
anism of toxicity associated with protease inhibitor
use, including lopinavir, is still poorly understood, but
is thought to be related to interference with some
cellular endogenous processes. For example, lopinavir
binds to lipoprotein receptor related protein (LPR),
impairing hepatic chylomicron uptake and triglyceride
clearance by LPR –lipoprotein lipase complex, causing
hyperlipidaemia [21]. In susceptible individuals, the
resulting hyperlipidaemia may induce diabetes [21].
Second, clinical manifestations of LPV/r toxicity are
also influenced by host susceptibility such as age, sex,
weight, race, advanced HIV disease, concomitant ART,
higher baseline triglyceride or cholesterol concentra-
tions, and genetic susceptibility [2,22,23]. Finally, we
hypothesize that the if the association between plasma
lopinavir concentrations and toxicity exists, it exists in
much lower concentrations, as the dose–response
curve is likely to be flat at the concentrations found in
our study. Therefore, the influence of lopinavir plasma
concentrations on lipids at therapeutic doses, is likely
to be small and larger studies are needed to detect the
small differences. Furthermore, recent data suggests
that lopinavir does not impair insulin sensitivity [7,8],
and therefore, the lack of an association between lopi-
navir and glucose concentrations is not surprising.
Our findings are in contrast with findings from a small
study conducted in 19 patients, which reported that
Table 2 Association between lopinavir trough concentrations and lipid and glucose concentrations
Univariate analyses Multivariate analyses
Variable Beta coefficient (95%CI) P value Beta coefficient (95% CI) P value
Total cholesterol −0.04 (−0.07 to 0.00) 0.07 −0.02 (−0.06 to 0.01) 0.21
Triglycerides −0.01 (−0.04 to 0.02) 0.53 −0.00 (−0.03 to 0.02) 0.86
Fasting glucose −0.01 (−0.04 to 0.02) 0.44 −0.00 (−0.03 to 0.02) 0.78
2 hour glucose −0.02 (−0.09 to 0.06) 0.64 0.00 (−0.05 to 0.06) 0.85
Adjusted for time after dose, age, sex and duration on lopinavir. In the multivariate model for 2 hour glucose, time after dose was an independent predictor
[β-coefficient 0.56 (95% CI 0.23 to 0.88), p= 0.001].
Figure 2 Proportion of participants with dyslipidaemia and dysglycaemia categorized by the lopinavir concentration below or above
the median (8μg/mL). The bar graphs show the proportion of participants (%) who had hypercholesterolaemia, hypertriglyceridaemia and
dysglycaemia in 42 participants with lopinavir below the median (fine checked bars) and in 42 participants with lopinavir concentrations equal to,
or above the median (course checked bars). There was no association between the lopinavir concentrations above the median and the metabolic
complications. The odds ratios for lopinavir above the median and the complications were: hypercholesterolaemia OR (95%CI): 0.49 (0.19 to 1.30);
hypertriglyceridaemia OR (95%CI): 0.56 (0.29 to 1.33); dysglycaemia OR (95 CI): 0.63 (0.24 to 1.63).
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lopinavir trough concentrations were higher in three
patients experiencing grade 3 or 4 lipid elevations [11].
A second larger study (n=126) found that patients with
fasting triglyceride concentrations above the median had
higher lopinavir trough concentrations, but no correl-
ation was found between lopinavir and cholesterol con-
centrations [10]. Four other studies reported findings
similar to ours, with no association between lopinavir
and lipid concentrations [12,17,24,25]. The older prote-
ase inhibitor indinavir is known to cause diabetes [5].
However, after 12 months of treatment with lopinavir,
none of the 73 patients included in another study devel-
oped diabetes [6]. Studies in healthy volunteers have
shown that insulin sensitivity wasn’t altered by lopinavir
in healthy HIV negative men [7,8]. However, a single
dose study in healthy volunteers showed that lopinavir
could inhibit glucose uptake acutely [9]. Data regarding
the association between lopinavir concentrations and
glucose metabolism are lacking.
Our study has several limitations. First, it is a cross
sectional study and we therefore cannot compare lipid
or glucose concentrations prior to lopinavir treatment.
Second, patients with known diabetes or dyslipidaemia
were excluded from the study, and it is possible that
lopinavir may have exacerbated a pre-existing metabolic
defect. Third, our sample size is relatively small, how-
ever, it is larger than most of the previous studies that
have investigated this association [11,17,19]. We aimed
to examine 50 participants to detect a correlation of
0.375. Our analyses used simple and multivariate regres-
sion analyses with various predictors, therefore we con-
tinued to slowly recruit eligible participants until the
end of the study. Fourth, we investigated associations
with pre-dose lopinavir concentrations and metabolic
parameters. The pharmacokinetic parameters area under
the curve or average steady state would be a better
measure of overall drug exposure. Lastly, the last dose of
lopinavir was not observed. To minimize recall bias, par-
ticipants were requested to record the time of last dose
on the appointment card for the day before pharmacoki-
netic sampling.
In conclusion, we did not find an association between
lopinavir concentrations and lipid and glucose concen-
trations. Larger prospective studies are needed to estab-
lish whether an association exists between lopinavir
concentrations and increasing lipids or glucose metabol-
ism changes.
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Abstract
Studies suggest that mitochondrial DNA (mtDNA) haplogroups are associated with antiretroviral therapy
(ART)-related metabolic complications and distal sensory polyneuropathy (DSP), but there have been few
studies in persons of African descent. We explored such associations in South African adults. Clinical and
laboratory data and DNA specimens from a cross-sectional study were used. Sequencing and Phylotree de-
termined African mtDNA subhaplogroups. Wilcoxon and regression analyses determined associations between
mtDNA subhaplogroups and ART-related complications. The 171 participants represented six major hap-
logroups: L0 (n = 78), L1 (n = 3), L2 (n = 30), L3 (n = 53), L4 (n = 1), and L5 (n = 6). Analyses were restricted to 161
participants representing L0, L2, and L3: 78% were female; the median age was 36 years. All had been exposed to
thymidine analogues, 42% were on lopinavir/ritonavir (lopinavir/r), and 58% were on either efavirenz or
nevirapine. Median (IQR) ART duration was 22 (14–36) months. Median fasting triglycerides were 1.60 (1.13–
1.75) and 1.04 (0.83–1.45) mmol/liter among L3e1 (n = 22) and other subhaplogroups, respectively ( p = 0.003).
Subhaplogroup L3e1 [adjusted OR (aOR) 3.16 (95% CI: 1.11–8.96); p = 0.03] and exposure to lopinavir/r [aOR
2.98 (95% CI: 1.02–8.96); p = 0.05] were independently associated with hypertriglyceridemia, after adjusting for
age, sex, and ART duration. There were no significant associations between mtDNA haplogroups and choles-
terol, dysglycemia, hyperlactatemia, or lipoatrophy, or DSP. Subhaplogroup L3e1 and lopinavir/r exposure
were independently associated with hypertriglyceridemia in black South Africans on ART. This is the first report
to link an African mtDNA variant with hypertriglyceridemia. If replicated, these findings may provide new
insights into host factors affecting metabolic complications.
Introduction
Exposure to antiretroviral therapy (ART) has beenassociated with metabolic adverse effects such as dysli-
pidemia, insulin resistance, dysglycemia, central fat accu-
mulation, peripheral fat loss (lipoatrophy), and peripheral
neuropathy.1,2 Many of these adverse effects are thought to
be related to nucleoside reverse transcriptase inhibitor
(NRTI)-related mitochondrial toxicity, at least in part due to
inhibition of mitochondrial DNA (mtDNA) gamma polymer-
ase and subsequent mitochondrial dysfunction.2 Other anti-
retroviral classes have also been associated with mitochondrial
dysfunction.3,4
Mitochondrial DNA is distinct from nuclear DNA and
codes for 13 polypeptides essential for oxidative phosphory-
lation.5 Mitochondrial DNA exhibits abundant genetic varia-
tion across the 16.6 kb mitochondrial genome. Human
mtDNA sequences have diverged over approximately the last
150,000 years due to natural selection and human migration,
resulting in distinct patterns of single nucleotide polymor-
phisms (SNPs), called haplogroups.6 Evidence for associations
between mtDNA haplogroups and outcomes in HIV-infected
participants has been reported for CD4 count recovery,7 AIDS
progression,8 and ART-related complications.9,10,11,12,13,14,15
Studies in HIV-uninfected populations (primarily European
and Asian) have reported associations between mtDNA
1University of Cape Town Medical School, Department of Medicine, University of Cape Town, Cape Town, South Africa.
2Vanderbilt University School of Medicine, Nashville, Tennessee.
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and metabolic complications including dyslipidemia and
diabetes.16,17,18,19,20
The majority of HIV-infected persons worldwide reside in
sub-Saharan Africa,21 but this region has been underrepre-
sented in genetic studies. Studies in African-Americans
showed associations between African mtDNA sub-
haplogroup L1c and peripheral neuropathy,15 and between
haplogroup L2 and CD4 T cell recovery.7 To date, no pub-
lished studies have investigated associations between African
mtDNA haplogroups and important metabolic complications
including lipoatrophy, dysglycemia, or dyslipidemia. In this
study, we report the prevalence of mtDNA haplogroups in a
South African population enrolled in an ART program, and
explore associations between African mtDNA and ART-
associated complications including metabolic complica-
tions and distal sensory polyneuropathy (DSP). Because
ART-associated adverse effects in HIV-infected persons,
and metabolic diseases in general, are believed to result in
part from mitochondrial dysfunction, we hypothesized that
mtDNA variation would be associated with susceptibility to
ART-associated lipoatrophy, dysglycemia, hypertriglycer-
idemia, and/or distal peripheral neuropathy in this South
African population.
Materials and Methods
Study design and participants
This analysis was conducted by retrospectively analyzing
data and specimens that had been collected during a pro-
spective, cross-sectional study of the prevalence of metabolic
and neuropathy complications of ART.22,23 Participants were
ambulatory HIV-infected African black adults who presented
for a routine follow-up visit at public-sector antiretroviral
clinics in Cape Town. Participants were recruited by conve-
nience sampling between February 2007 and September 2008.
They were eligible if they were on ART therapy for at least
6 months, with no renal or hepatic disease, no active oppor-
tunistic infections, or no known history of diabetes or dysli-
pidemia. Participants on lipid or glucose-lowering therapy
were also excluded. The University of Cape Town research
ethics committee approved the primary study and all partic-
ipants who signed informed consent for the genetic study and
had clinical and laboratory evaluations and/or whole body
dual-energy X-ray absorptiometry (DEXA) were included in
this analysis. The Vanderbilt University Institutional Review
Board approved the use of de-identified DNA and clinical
data for these analyses.
Clinical and laboratory evaluations
Participants fasted overnight and underwent an oral glu-
cose tolerance test (OGTT). Impaired fasting glucose (IFG),
impaired glucose tolerance (IGT), and diabetes were defined
according to the American Diabetes Association criteria.24
Fasting triglyceride concentrations were determined at the
start of the OGTT and were measured at the National Health
Laboratory Services. Hypertriglyceridemia was defined ac-
cording to NCEP III criteria.25 Point-of-care measurement of
lactate was done before glucose loading using the Accutrend
lactate meter (Roche, Basel, Switzerland). Hyperlactatemia
was defined as a lactate concentration ‡ 2.5 mmol/liter.26 For
the present study, DSP was defined as the presence of at least
two of the following signs: reduced or absent reflexes and
impaired vibratory or pinprick sensation with or without
neuropathic symptoms (pain, paresthesia, or numbness). A
DSP diagnosis was considered only if signs and symptoms
were bilateral, of symmetrical onset, and present for at least
2 weeks. Limb fat was measured by DEXA scan and per-
centage of limb fat was used to determine lipoatrophy, which
was defined as percentage limb fat below the median strati-
fied by sex. We reviewed medical records to determine du-
ration on antiretroviral therapy, current CD4 + lymphocyte
counts, and viral load within 3 months of the study visit,
where available.
Mitochondrial DNA isolation and sequencing
Chromosomal and mtDNA were isolated from buffy coats
using Maxwell16! DNA Purification Kits (Promega Cor-
poration, Madison, WI). Full mitochondrial DNA sequencing
was performed using the GeneChip Human Resequencing
Array v2.0 (Affymetrix Inc., Santa Clara, CA). The full
sequence data were used to assign haplogroups and sub-
haplogroups based on PhyloTree.27
Statistical analysis
Kruskal–Wallis and Wilcoxon rank-sum tests were used to
compare medians between haplogroups. Linear regression
models were used to compare continuous outcomes between
subhaplogroups. For analysis of binary outcomes, a case-
control design was used. The Pearson Chi-squared test was
used to compare proportions of subjects with dichotomous
metabolic outcomes. Logistic regression models were fitted to
assess the association between subhaplogroups and dysgly-
cemia, DSP, hyperlactatemia, hypertriglyceridemia, and li-
poatrophy. Age, sex, lopinavir exposure, and duration on
ART were included in all multivariate regression models. Age
and sex were included a priori as potential confounders.
Lopinavir was included as the potential confounder as it had
been associated with metabolic complications. The duration
on ART was included in all multivariate models as it differed
between the major haplogroups. Subhaplogroups with fewer
than 10 participants were excluded from analyses. Analyses
were performed using Stata release 11 (StataCorp LP, College
Station TX). All tests were two-sided, and a p value < 0.05 was
considered significant. As this was an exploratory study, we
did not formally correct for multiple comparisons.
Results
Participant characteristics and mitochondrial haplogroups
A total of 219 participants provided DNA for analysis, and
mitochondrial sequencing was successful in 171 (78%). The
primary reason for lack of sequencing data was insufficient or
poor quality DNA. Figure 1 shows the flow chart of partici-
pants in this study. We restricted our analyses to the 161
participants who belonged to the L0 (n = 78), L2 (30), and L3
(53) major haplogroups (Table 1) because the numbers in the
other haplogroups were small [L4 (1), L1 (3), and L5 (6)]. Most
participants (78%) were female, which reflects the population
treated in the referring clinics. Current ART regimens con-
tained efavirenz, nevirapine, and lopinavir/ritonavir in 33%,
25%, and 42%, respectively. Consistent with South African
HIV treatment guidelines at the time, most participants on a
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first-line regimen were treated with stavudine/lamivudine
(66%) or zidovudine/lamivudine (34%) combinations as the
NRTI backbone, while most of those on second-line regimens
were treated with zidovudine/didanosine (58%) or zidovu-
dine/lamivudine (24%) combinations. Duration on ART dif-
fered across haplogroups (Kruskal–Wallis p = 0.02; Table 1),
with the L0 major haplogroup having significantly shorter
ART duration ( p = 0.01), and the L3 major haplogroup having
longer ART duration compared to the others ( p = 0.01).
However, the duration on lopinavir/ritonavir did not differ
among the major haplogroups (Kruskal–Wallis p = 0.88; Table
1). The L2 major haplogroup had fewer females than other
haplogroups ( p = 0.04). Otherwise, baseline characteristics did
not differ significantly by major mtDNA haplogroup.
Metabolic complications and mitochondrial haplogroups
Median [interquartile range (IQR)] lipid values in this co-
hort were total cholesterol 4.33 (3.79–5.28) mmol/liter, LDL
2.71 (2.20–3.20) mmol/liter, HDL 1.03 (0.81–1.29) mmol/liter,
and triglycerides 1.11 (0.85–1.59) mmol/liter. Simple regres-
sion analyses showed no statistically significant associations
between the metabolic parameters and the three haplogroups
( p > 0.05 for each analysis, Table 2).
Metabolic complications were common in this cohort.
Hypercholesterolemia was present in 31%, hypertriglycer-
idemia in 18%, dysglycemia in 34%, and hyperlactatemia in
28%. Table 3 shows unadjusted and adjusted odds ratios for
metabolic complications. In these analyses, there was a sta-
tistically significant association between the L3 haplogroup
and hypertriglyceridemia [unadjusted odds ratio (OR) 2.58
(95% CI 1.14–5.84), p = 0.02; Table 3]. This association re-
mained significant after adjusting for age, sex, current
lopinavir-based ART, and overall ART duration [adjusted
odds ratio (aOR) 2.44(95% CI 1.03–5.77), p = 0.04]. As expected,
lopinavir/r use was also independently associated with hy-
pertriglyceridemia [aOR 3.55 (95% CI 1.21–10.39), p = 0.02].
Every mitochondrial haplogroup is further divided into
subhaplogroups.27 A weak association with a haplogroup
might be driven by a stronger association with a sub-
haplogroup. Because of the availability of full mtDNA se-
quence data in this study, we were able to explore whether a
subhaplogroup within L3 was associated with hyper-
triglyceridemia. The frequencies of the L3 subhaplogroups in
the study population were L3e1 (23), L3e2 (16), L3d1 (4), L3d3
(3), L3e4 (3), L3f1 (2), L3b1 (1), and L3e3 (1). Based on the
infrequency of non-L3e1 and non-L3e2 subhaplogroups, we
chose to analyze subhaplogroups L3e1 and L3e2 separately,
and to combine the remaining participants as ‘‘other L3 sub-
haplogroups.’’
Figure 2 shows the triglyceride concentrations (Fig. 2A) and
hypertriglyceridemia (Fig. 2B) in the L3e1 subhaplogroup,
other L3 subhaplogroups, and the haplogroups L0 and L2.
The triglyceride concentrations differed significantly between
the mtDNA subhaplogroups (Kruskal–Wallis p = 0.047). The
L3e1 subhaplogroup had significantly higher triglyceride
concentrations compared to other subhaplogroups combined
(Wilcoxon p = 0.003; Fig. 2A). Linear regression showed that
mean difference in triglyceride concentrations between the
L3e1 subhaplogroup and other subhaplogroups combined
was 0.40 mmol/liter [(95% CI 0.06–0.75 mmol/liter), p = 0.02].
After adjusting for age, sex, lopinavir/ritonavir-based ART,
and ART duration; the association was no longer statistically
significant [mean difference 0.35 (95% CI - 0.01–0.72) mmol/
liter, p = 0.06]. The prevalence of hypertriglyceridemia in the
L0 and L2 haplogroups and L3 subhaplogroups was L0
(13%) and L2 (17%), L3e1 (41%), L3e2 (19%), and other L3
subhaplogroups (23%). When comparing L3e1 to other sub-
haplogroups combined, the prevalence of hypertriglycer-
idemia was 41% and 15%, respectively ( p = 0.004; Fig. 2B). By
logistic regression, there was a statistically significant associ-
ation between the L3e1 subhaplogroup and hypertriglycer-
idemia [unadjusted OR 3.82 (95% CI 1.45–10.10), p = 0.007].
When adjusted for age, sex, current lopinavir treatment, and
ART duration, there remained a significant association with
the L3e1 subhaplogroup [aOR 3.16 (95% CI 1.11–8.96),
p = 0.03]. Lopinavir treatment was also independently asso-
ciated with hypertriglyceridemia [aOR 2.97 (95% CI 1.02–
8.69), p = 0.05]. Figure 3 summarizes various multivariate
models for the metabolic complications.
There were no other significant associations between hap-
logroups and metabolic complications other than hyper-
triglyceridemia. In multivariate analyses for each haplogroup,
increasing age was an independent predictor of dysglycemia
after adjusting for mtDNA haplogroup, sex, current lopina-
vir/r treatment, and duration on ART ( p for age in each
model < 0.05; Fig. 3C).
Peripheral lipoatrophy and mitochondrial haplogroups
Overall median (IQR) percentage limb fat by DEXA was 17
(12–21)% (Table 1). Percentage limb fat differed by sex, with
males having a median (IQR) of 8 (6–10)% and females having
a median (IQR) of 18 (15–22)%. Initial unadjusted analyses
demonstrated significantly lower percentage limb fat in the L2
haplogroup compared with the other haplogroups ( p = 0.04).
However, the L2 haplogroup also had a lower percentage of
females than the other haplogroups ( p = 0.04). In view of these
findings, peripheral lipoatrophy was defined as percentage
limb fat below the median in sex-stratified populations (male
n = 30; female n = 101). Logistic regression analyses stratified
by sex showed no associations between L2 haplogroup and
peripheral lipoatrophy by this definition [males: unadjusted
OR 1.33 (95% CI 0.30–5.91), p = 0.71; females: unadjusted OR
1.17 (95% CI 0.41–3.36), p = 0.71]. Adjusting for age and ART
FIG. 1. Flow chart of the study population.
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Table 1. Study Population Characteristics Including Metabolic and Neuropathic Data, by Major Haplogroups
Study population submitted for sequencing Major haplogroups analyzed
All subjects Subjects L0, L2, L3 L0 L2 L3
Variable N = 219 N = 161 N = 78 N = 30 N = 53
Age (years) 36 (31–42) 36 (32–42) 35 (31–40) 36 (31–41) 37 (32–44)
Female n/N (%)a 179/219 (82) 125/161 (78) 63/78 (80) 19/30 (63) 43/53 (81)
BMI (kg/m2) 26 (23–31) 25 (23–28) 25 (23–29) 24 (21–28) 27 (24–34)
N = 216 N = 158 N = 77 N = 30 N = 51
CD4 count at start of
treatment (cells/mm3)
97 (48–151) 97 (54–153) 93 (40–155) 79 (33–130) 113 (75–179)
N = 199 N = 146 N = 69 N = 28 N = 49
CD4 count at study
enrollment (cells/mm3)
385 (247–520) 382 (247–518) 346 (238–510) 349 (201–518) 447 (288–524)
N = 217 N = 160 N = 77 N = 30 N = 53
Viral load (VL) log10
VL before ART
(copies/ml)
4.64 (3.68–5.26) 4.97 (4.49–5.45) 4.98 (4.56–5.49) 4.98 (4.55–5.38) 4.85 (4.48–5.33)
N = 100 N = 75 N = 30 N = 14 N = 31
VL < 400 at study
enrollment n/N (%)
142/163 (87) 109/127 (86) 50/58 (86) 23/27 (85) 36/42 (85)










Waist:hip ratio 0.88 (0.84–0.94) 0.88 (0.83–0.94) 0.86 (0.82–0.94) 0.88 (0.84–0.93) 0.89 (0.85–0.94)
NRTI backbone n/N (%)
Stavudine/lamivudine 97/218 (45) 69/160 (43) 41/77 (53) 8/30 (27) 20/53 (38)
Zidovudine/lamivudine 66/218 (30) 46/160 (28) 19/77 (25) 10/30 (33) 17/53 (32)
Zidovudine/didanosine 46/218 (21) 38/160 (23) 12/77 (16) 12/30 (40) 14/53 (26)
Other 9/218 (4) 7/160 (5) 5/77 (7) 0/30 (0) 2/53 (4)
NNRTI/PI n/N (%)
Efavirenz 82/219 (37) 54/161 (33) 27/78 (35) 6/30 (20) 21/53 (40)
Nevirapine 57/219 (26) 40/161 (25) 24/78 (30) 9/30 (30) 7/53 (13)
Lopinavir/ritonavir 80/219 (37) 67/161 (42) 27/78 (35) 15/30 (50) 25/53 (47)
Duration (months)
Stavudine 15 (9–23) 15 (10–22) 14 (9–19) 14 (10–21) 17 (12–30)
N = 187 N = 137 N = 70 N = 25 N = 42
Zidovudine 16 (10–26) 16 (10–27) 16 (11–27) 16 (7–27) 16 (10–26)
N = 114 N = 88 N = 35 N = 22 N = 31
Lopinavir/ritonavir 18 (10–26) 18.5 (10–26) 18 (12–30) 18 (7–27) 20 (10.5–26)
N = 76 N = 66 N = 27 N = 15 N = 24
Any ARTb 23 (14–33) 22 (14–36) 19 (11–30) 22 (15–33) 30 (17–41)
N = 214 N = 157 N = 76 N = 30 N = 51
Lipids (mmol/liter) N = 217 N = 159 N = 78 N = 30 N = 51
Total cholesterol 4.34 (3.75–5.25) 4.33 (3.79–5.28) 4.34 (3.86–5.15) 4.23 (3.95–4.72) 4.45 (3.66–5.49)
LDL-C 2.70 (2.20–3.22) 2.71 (2.20–3.20) 2.71 (2.20–3.08) 2.75 (2.21–3.10) 2.80 (2.19–3.49)
HDL-C 1.03 (0.82–1.30) 1.03 (0.81–1.29) 1.07 (0.88–1.27) 0.96 (0.80–1.29) 1.01 (0.75–1.32)
Triglycerides 1.11 (0.85–1.49) 1.11 (0.85–1.59) 1.07 (0.87–1.41) 0.99 (0.78–1.62) 1.23 (0.87–1.81)
Glucose (mmol/liter)
Fasting 5.3 (4.8–5.6) 5.1 (4.8–5.6) 5.0 (4.7–5.4) 5.3 (4.9–5.6) 5.1 (4.8–5.6)
N = 217 N = 159 N = 78 N = 30 N = 51
2 h 6.1 (5.2–7.1) 6.0 (5.2–7.3) 5.8 (5.05–6.95) 6.15 (5.70–7.80) 6.2 (5.3–7.5)
N = 215 N = 157 N = 76 N = 30 N = 51
Lactate (mmol/liter) 1.9 (1.3–2.5) 1.9 (1.3–2.5) 1.9 (1.3–2.5) 1.9 (1.7–2.5) 1.8 (1.3–2.8)
N = 207 N = 155 N = 75 N = 29 N = 51
Percentage limb fat (%)c 17 (12–21) 17 (12–21) 18 (14–21) 13 (9–20) 17 (13–21)
N = 172 N = 131 N = 62 N = 28 N = 41
DSP n/N (%) 149/219 (68) 106/161 (65) 54/78 (69) 21/30 (70) 31/53 (58)
aChi-square test shows that the L2 major haplogroup had fewer females than other haplogroups ( p = 0.04).
bKruskal–Wallis test showed that ART duration differed across the haplogroups ( p = 0.02). Wilcoxon rank sum test showed that the L0
major haplogroup had significantly shorter ART duration than others ( p = 0.01) and the L3 major haplogroup had significantly longer ART
duration than the others ( p = 0.01).
cWilcoxon rank sum test showed that the L2 major haplogroup had significantly lower percentage limb fat than other groups. Other
baseline characteristics did not significantly differ by major mtDNA haplogroup.
Data are reported in median (IQR) unless specified. When N is not specified, there was no missing data. BMI, body mass index; LDL-C,
low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI,
nonnucleoside reverse transcriptase inhibitor; ART, antiretroviral therapy; PI, protease inhibitor; DSP, distal sensory polyneuropathy.
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regimen also did not show significant associations [males:
unadjusted OR 1.17 (95% CI 0.24–5.72), p = 0.85; females: un-
adjusted OR 1.28 (95% CI 0.46–3.61), p = 0.64].
Distal sensory polyneuropathy (DSP) and
mitochondrial haplogroups
The overall prevalence of DSP was 66% (Table 1). There
were no statistically significant associations between DSP and
mitochondrial haplogroups, either when treated as a com-
posite variable or when assessing symptomatic and asymp-
tomatic DSP separately (all p > 0.1; data not shown).
Discussion
We explored associations between African mtDNA
haplogroups and ART-related complications in a cohort of
HIV-infected South African adults. We found that the L3e1
subhaplogroup was significantly associated with hyper-
triglyceridemia independent of lopinavir/ritonavir expo-
sure. This is the first report to link an African mtDNA variant
to hypertriglyceridemia. We found no associations between
mtDNA haplogroups and other metabolic complications,
including hypercholesterolemia, dysglycemia, lipoatrophy,
or DSP.
Mitochondrial DNA haplogroups have been mostly stud-
ied to understand human evolution and migration.28 How-
ever, recent studies have investigated the association of
mtDNA haplogroups with human diseases and longevity.7–15
We described the frequencies of the mitochondrial hap-
logroups in our South African cohort recruited from two Cape
Town clinics, the majority of which belonged to the L0 hap-
logroup. There are limited data regarding the distribution of
the mitochondrial haplogroups in the South African popula-
tion. However, the distribution of mitochondrial haplogroups
we found was similar to a recently published South African
study conducted in 71 children.29 None of the participants
analyzed belonged to the European mitochondrial hap-
logroups.
The association between L3e1 subhaplogroup and hyper-
triglyceridemia was independent of LPV/r use, which is a
well-documented cause of elevated triglycerides.30 In a recent
study of 174 non-Hispanic white HIV-infected clinical trial
participants in the United States, the European mtDNA hap-
logroup I was associated with a decrease in triglycerides over
96 weeks of ART when compared with non-I mtDNA hap-
logroups.10 To the best of our knowledge, the association
between African mtDNA haplogroups and hypertriglycer-
idemia has not previously been studied.
Table 2. Univariate Analyses of Metabolic Complications and Major Mitochondrial Haplogroups
Major haplogroups
L0 L2 L3
Variable Beta coeff (95% CI) p Beta coeff (95% CI) p Beta coeff (95% CI) p
Total cholesterol - 0.01 ( - 0.47–0.27) 0.59 - 0.12 ( - 0.51–0.26) 0.53 0.20 ( - 0.25–0.65) 0.38
Triglycerides - 0.10 ( - 0.34–0.13) 0.39 - 0.11 ( - 0.35–0.13) 0.35 0.20 ( - 0.06–0.46) 0.13
Fasting glucose - 0.18 ( - 0.63–0.27) 0.42 - 0.06 ( - 0.44–0.30) 0.73 0.26 ( - 0.40–0.91) 0.44
2 h glucose - 0.69 ( - 1.60–0.22) 0.14 0.32 ( - 0.62–1.27) 0.50 0.56 ( - 0.70–1.81) 0.38
Lactate - 0.07 ( - 0.38–0.24) 0.65 - 0.01 ( - 0.35–0.33) 0.95 0.09 ( - 0.28–0.46) 0.64
Fasting glucose and lipid data were available from 159 participants. For 2 h glucose and lactate, data were available only from 157 and 155
participants, respectively. All variables were measured in mmol/liter. p values are comparing variables for each haplogroup with the other
two haplogroups combined.
Table 3. Univariate and Multivariate Analyses of Metabolic Complications and Major Haplogroups
Major haplogroups
L0 L2 L3



































































Adjusted for age, sex, lopinavir treatment, and treatment duration. p values are comparing variables for each haplogroup with the other
two haplogroups combined.
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FIG. 2. Fasting triglyceride concentrations and hypertriglyceridemia by mitochondrial DNA (mtDNA) subhaplogroups. (A)
Box plots of triglyceride concentrations in the L3e1 subhaplogroup, other L3 subhaplogroups, as well at the other hap-
logroups L0 and L2. Boxes represents medians and interquartile ranges; whiskers are the range. Triglycerides differed by
mtDNA haplogroups (Kruskal–Wallis p = 0.047), with L3e1 having significantly higher concentrations than other hap-
logroups (Wilcoxon p = 0.003). The gray dashed line indicates the cutoff value of 1.7 mmol/liter used to categorize hyper-
triglyceridemia.25 (B) The proportion of participants with hypertriglyceridemia by mtDNA subhaplogroups, with 41% in the
L3e1 subhaplogroup and 15% in other subhaplogroups combined (Chi square test p = 0.004).
FIG. 3. Associations between mitochondrial DNA subhaplogroups and metabolic complications in HIV-infected South
African adults on antiretroviral therapy (ART), shown as adjusted odds ratios (aORs). aORs were obtained from separate
models: L0, L2, L3, and L3e1. The covariates age, sex, lopinavir/ritonavir (LPV/r) exposure, and ART duration displayed in
(A) are from the L3e1 model. (B–D) The same covariates are from the L0 model. After adjusting for age, sex, LPV/r exposure,
and ART duration, L3 [aOR 2.44 (95% CI: 1.03–5.77) and p = 0.04], L3e1 [aOR 3.16 (95% CI: 1.11–8.96); p = 0.03] were
independently associated with hypertriglyceridemia. LPV/r exposure [aOR 2.97 (95% CI: 1.02–8.69); p = 0.047] was also
independently associated with hypertriglyceridemia and this was consistent in all subhaplogroup models.
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An association between an mtDNA polymorphism and
plasma triglycerides was previously reported in a Canadian
cohort.31 Variation at mtDNA position 16517 was associated
with significantly higher fasting plasma triglyceride concen-
trations in this population. These data support the hypothesis
that mitochondrial DNA variation may influence fatty acid
and lipid metabolism. Fatty acids derived from plasma tri-
glycerides are precursors of acyl CoA, which is used in the
mitochondrial ß oxidation cycle of fatty acid metabolism.
Genetic variation affecting mitochondrial function might also
affect the utilization of fatty acid in ß oxidation.31 Differences
in cellular utilization may then alter the demand of fatty acids
from triglycerides, which may influence plasma concentra-
tions.31 However, the exact mechanism is still unclear.
We found no association between mitochondrial DNA
haplogroups and hypercholesterolemia. In the study refer-
enced above, European mtDNA haplogroup I was associated
with higher baseline (pre-ART) non-HDL cholesterol and a
significant decrease in non-HDL cholesterol after 96 weeks of
ART.10 In a study of 83 elite athletes and 61 patients with
sedentary lifestyles, mtDNA clade HV was significantly as-
sociated with higher LDL cholesterol in the elite athletes, but
not in those with a sedentary lifestyle.19 The lack of an asso-
ciation between mtDNA haplogroups and hypercholester-
olemia observed in our cohort may be due to several factors.
First, the studies discussed above investigated only European
haplogroups,10 not African haplogroups. Second, nuclear
genetic factors known to influence cholesterol (e.g., LPL,
APOC3, and APOA2) may have a stronger influence on cho-
lesterol than mitochondrial genetic variation, or mediate re-
lationships between mitochondrial variation and phenotype.
Third, data on lifestyle factors known to influence plasma
cholesterol were not available in our cohort.
We observed no statistically significant associations be-
tween African mtDNA haplogroups and fasting dysglycemia.
Multivariate analyses showed that older age was an inde-
pendent predictor of dysglycemia, independent of hap-
logroup, sex, lopinavir treatment, or duration on ART. To our
knowledge, this is the first study to investigate an association
between this outcome and mtDNA haplogroups in an African
cohort. Several inborn mitochondrial diseases include diabe-
tes,32 and common mitochondrial DNA mutations have also
been associated with type 2 diabetes mellitus in Asians and
Europeans.33,34 Studies investigating mitochondrial hap-
logroups and type 2 diabetes have shown conflicting results.
Although the prevalence of dysglycemia was high (33%) in
our cohort, only 8 of 159 participants had diabetes and
therefore diabetes was not included as an outcome in this
analysis. Hyperlactatemia is a recognized consequence of
mitochondrial dysfunction associated with d-drug use.35 We
found no association between African mtDNA haplogroups
and hyperlactatemia, which is similar to the finding from
another South African study.36
There are inconsistent data regarding the influence of
specific European mtDNA haplogroups on lipoatrophy.11,12
The AIDS Clinical Trials Group (ACTG) cohort found that the
mtDNA haplogroup J tended to be protective against lipoa-
trophy.11 The Multicenter AIDS Cohort Study (MACS), con-
ducted in 410 U.S. men (100% white), found that mtDNA
haplogroup H was significantly associated with clinically
defined lipoatrophy in the arms and legs, and that mtDNA
haplogroup T tended to be protective.12 In contrast, a recent
Italian study showed that mtDNA haplogroup T tended to
increase the risk of lipoatrophy when compared to mtDNA
haplogroup H.37 These studies are limited by diverse popu-
lations and heterogeneous outcome ascertainment. It is hy-
pothesized that variations in mtDNA haplogroups may
influence lipoatrophy at the adipocyte level, affecting cellular
energy production efficiency, reactive oxygen species gener-
ation, and/or levels of apoptosis, all of which may be exac-
erbated by use of NRTIs. However, the exact mechanism
remains unclear. The lack of an association between African
mtDNA haplogroups and lipoatrophy could have been
influenced by the way lipoatrophy was defined in our cohort.
Due to significant differences between men and women, li-
poatrophy was defined as percentage limb fat below the
median in the sex-stratified populations. We also compared
groups in the lowest and highest tertiles and quartiles and
found no significant associations (data not shown). Notably,
only a subset had DEXA scans, therefore we had limited
power to detect differences. Larger prospective studies are
needed to determine if an association between lipoatrophy
and African mtDNA haplogroups exists.
Finally, we found no association between African mtDNA
haplogroups and DSP. A study conducted in non-Hispanic
black participants from ACTG study 384 reported an associ-
ation between the African mtDNA L1c and increased sus-
ceptibility to peripheral neuropathy during NRTI treatment.15
As discussed above, the L1 haplogroup was found in only
three participants in our cohort and they were excluded from
our analyses, so we were unable to replicate this reported
association. Here, DSP was frequent and no association was
observed with a particular haplogroup. We were also unable
to adjust for the effect of d-drugs, an important cause of DSP,
as > 90% of participants had been exposed to stavudine and/
or didanosine. All participants were examined by either of
two trained clinicians, and DSP was more rigorously defined
compared with many other reports. The prevalence of DSP in
our cohort was high (66%), compared with that reported in
the ACTG study (33%).15
Our study had several limitations. The design was cross-
sectional, with participants of different HIV disease stages
and different ART durations. We excluded ART-naive par-
ticipants and participants with current opportunistic infec-
tions, known hepatic or renal disease, or with known
dyslipidemia (or taking lipid-lowering therapy) or dysglyce-
mia (or taking antidiabetic drugs). Viral load data were
missing in the majority of participants, and were therefore not
included in the analysis as a covariate. Our sample size was
relatively small and we did not formally adjust for multiple
comparisons. However, when considering the five mtDNA
subhaplogroups we analyzed, only the unadjusted analyses
between subhaplogroup L3e1 and triglycerides concentra-
tions (Wilcoxon p = 0.003), or hypertriglyceridemia ( p = 0.007)
remained significant when our level of significance was cor-
rected to p < 0.01.
In conclusion, we observed a novel association between
African mtDNA subhaplogroup L3e1 and hypertriglycer-
idemia. Functional studies are needed to unravel the mecha-
nism by which this subhaplogroup may increase triglycerides.
We did not find associations between African mtDNA hap-
logroups and the other ART-related complications studied,
but we may have been underpowered to identify smaller as-
sociations. Larger studies in sub-Saharan Africa, which has
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the highest HIV burden in the world but few pharmacoge-
nomic studies, are needed to confirm the association we found
between African mtDNA subhaplogroup L3e1 and hyper-
triglyceridemia, and to explore associations between mtDNA
haplogroups and other HIV- and ART-related complications.
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Genetic factors, notably CYP2B6 516G→T [rs3745274] and 983T→C
[rs28399499], explain much of the interindividual variability in efavirenz
pharmacokinetics, but data from Africa are limited. We characterized
relationships between genetic polymorphisms and plasma efavirenz
concentrations in HIV-infected Black South African adults and children.
METHODS
Steady-state mid-dosing interval efavirenz concentrations were measured. We
genotyped 241 polymorphisms in genes potentially relevant to efavirenz
metabolism and transport, including ABCB1, CYP2A6, CYP2B6, CYP3A4, CYP3A5,
NR1I2 and NR1I3.
RESULTS
Among 113 participants (59 adults and 54 children), minor allele frequencies for
CYP2B6 516G→T, 983T→C, and 15582C→T [rs4803419] were 0.36, 0.07, and 0.09,
respectively. Based on composite CYP2B6 15582/516/983 genotype, there were 33
extensive metabolizer, 62 intermediate metabolizer and 18 slow metabolizer
genotypes. Median (IQR) mid-dose efavirenz concentrations were 1.44 (1.21–1.93)
μg ml–1, 2.08 (1.68–2.94) μg ml–1 and 7.26 (4.82–8.34) μg ml–1 for extensive, inter-
mediate and slow metabolizers, respectively. In univariate analyses, a model that
included composite genotype best predicted efavirenz concentrations (β = 0.28,
95% CI 0.21, 0.35, P= 2.4 × 10–11). Among individual CYP2B6 polymorphisms,
516G→T best predicted efavirenz concentrations (β = 0.22, 95% CI 0.13, 0.30,
P= 1.27 × 10!6). There was also associations with 983T→C (β = 0.27, 95% CI 0.10,
0.44, P = 0.002) and 15582C→T (β = 0.11, 95% CI 0.01, 0.22, P= 0.04). Associations
were consistent in adults and children. No other polymorphisms were indepen-
dently associated with efavirenz concentrations.
CONCLUSIONS
Composite CYP2B6 genotype based on CYP2B6 516G→T, 983T→C, and
15582C→T best described efavirenz exposure in HIV-infected Black South
African adults and children.
WHAT IS ALREADY KNOWN ABOUT
THE SUBJECT
• The polymorphisms CYP2B6 516G→T
(rs3745274) and 983T→C (rs28399499) are
strongly associated with plasma efavirenz
concentrations, but do not entirely explain
interindividual variability.
• A recent genome-wide association study
implicated CYP2B6 15582C→T (rs4803419)
as an independent predictor of efavirenz
trough concentrations.
• Reported pharmacokinetic associations
beyond CYP2B6 are inconsistent.
WHAT THIS STUDY ADDS
• We provide evidence to show that CYP2B6
15582C→T is associated with plasma
efavirenz concentrations in Black South
Africans, in addition to CYP2B6 516G→T and
983T→C.
• We show that genetic associations are
consistent in adults and children.
• We found no additional associations with
plasma efavirenz concentrations beyond
these CYP2B6 polymorphisms.
British Journal of Clinical
Pharmacology
DOI:10.1111/bcp.12590
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Introduction
Efavirenz is extensively prescribed for HIV-1 infection
worldwide. It is metabolized primarily by cytochrome
P450 (CYP) 2B6 [1]. Analyses with AIDS Clinical Trials
Group (ACTG) protocol 5097s first showed that the
non-synonymous polymorphism CYP2B6 516G→T
(rs3745274) was strongly associated with increased
plasma efavirenz exposure [2]. Many studies have since
replicated this association [3–17]. The CYP2B6 516G→T
polymorphism is more frequent with African ancestry
than with European ancestry [18], which largely
explains the greater mean plasma efavirenz concentra-
tions reported among populations of African descent
[19, 20]. A less frequent CYP2B6 polymorphism,
983T→C (rs28399499), also predicts increased plasma
efavirenz exposure [9, 13, 16, 21–25]. The CYP2B6 983
C allele is found almost exclusively with African
ancestry, where it is still much less frequent than
516G→T [18]. A recent genome-wide association
study of White, Black and Hispanic adults in the
United States showed that a third polymorphism,
CYP2B6 15582C→T (rs4803419), was also associated
with estimated efavirenz trough concentrations inde-
pendent of 516G→T and 983T→C [26].
Additional CYP2B6 polymorphisms suggested to
affect CYP2B6 activity have been extremely infrequent
[21, 27, 28], or have not predicted plasma efavirenz expo-
sure [2, 29, 30]. Polymorphisms in genes beyond CYP2B6
reported to affect efavirenz pharmacokinetics include
CYP2A6 [7, 30], CYP3A5 [2], UGT2B7 [7] and CAR [31],
although results have been inconsistent. The genome-wide
associations study noted above did not identify additional
associations in or beyond CYP2B6 [26].
Data from Africa have repeatedly replicated the
association between efavirenz exposure and both
CYP2B6 516G→T [7–17, 24, 25] and CYP2B6 983T→C
[9, 13, 16, 21, 24, 25], but data from Africa beyond these
two polymorphisms are limited. We characterized rela-
tionships between genetic polymorphisms and plasma
efavirenz concentrations among HIV-infected adults and
children in South Africa.
Methods
Study participants
We included adults and children who had been enrolled
in two observational studies. In the adult study, adults
from the public sector antiretroviral therapy (ART) pro-
gramme were enrolled in a cross sectional study to evalu-
ate associations between plasma efavirenz concentrations
and metabolic complications. Eligible participants were
on efavirenz-based therapy for at least 1 month, and were
excluded for renal or hepatic disease, active opportunistic
infections, known diabetes or dyslipidaemia, self-reported
non-adherence, pregnancy, or concomitant drugs with
the potential to interact with efavirenz.
In the paediatric study, African children (aged 3–15
years and weighing more than 10 kg) on efavirenz-based
therapy with or without rifampicin-based anti-
tuberculosis therapy were enrolled to evaluate the effect
of rifampicin-based antituberculosis therapy on efavirenz
concentrations [32]. The present analyses included only
data from children who were not receiving rifampicin.
All participants self-identified as Black. This study com-
plied with the Helsinki Declaration, was approved by insti-
tutional review boards for each site, and participants or
their parents gave written informed consent or assent.
Characterization of genetic polymorphisms
Human DNA was extracted from buffy coats using the
Wizard® Genomic DNA purification kit (Promega, Madison,
WI, USA). A total of 241 polymorphisms (70 in ABCB1 (also
called MDR1), 22 in CYP2A6, 54 in CYP2B6, one in CYP2C19,
23 in CYP3A4, one in CYP3A5, 31 in NR1I2 (also called PXR)
and 39 in NR1I3 (also called CAR)) were successfully geno-
typed in the Vanderbilt DNA Resources Core using
MassARRAY® iPLEX Gold (Sequenom, Inc., San Diego,
California, USA). Our strategy for genotyping was as follows:
For CYP2B6, ABCB1 and NR1I2 we tagged each entire gene
using SeattleSNPs [33] using a cosmopolitan strategy
across populations (Yoruba, Asian, African-American,
European-American and Hispanic) with a 5% allelic fre-
quency cut-off, a 0.80 threshold for r2, 85% data conver-
gence for tagging polymorphisms and 70% data
convergence for clustering. For CYP2B6 we included 5 kB
in each 5’ and 3’ untranslated regions (UTR), and for ABCB1
and NR1I2 20 kB in each UTR. For CYP2B6, additional poly-
morphisms of interest (but that were not extremely infre-
quent) were added based on a previous report [3], as
were polymorphisms with at least 5% allelic frequency in
20 kB of the 5’ UTR identified using Ensembl Genome
Browser [34] and upstream polymorphisms possibly associ-
ated with CYP2B6 expression [35]. We also included ABCB1
3435C→T (rs1045642) and 2677G/T/A (rs2032582),
CYP2C19 681G→A (rs4244285) and CYP3A5 6986A→G
(rs776746). (CYP2C19 681G→A was part of the already de-
signed multiplex assay, but was not expected to affect
efavirenz exposure). The final Sequenom assay design is
available upon request. Laboratory personnel with no
knowledge of clinical data performed genotyping. Ample
duplicate and blank assays were included to assure validity.
Polymorphisms were excluded for genotyping efficiency
less than 95%.
Composite CYP2B6 15582/516/983 genotypes were
assigned as follows: extensive metabolizer genotype
(15582CC-516GG-983TT or 15582CT-516GG-983TT), in-
termediate metabolizer genotype (15582TT-516GG-
983TT, 15582CC-516GT-983TT, 15582CC-516GG-983CT,
15582CT-516GT-983TT or 15582CT-516GG-983CT) and
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slow metabolizer genotype (15582CC-516TT-983TT,
15582CC-516GT-983CT or 15582CC-516GG-983CC) [26].
Efavirenz concentrations
Plasma efavirenz concentrations were measured using
liquid chromatography with tandem mass spectrometry
(LC/MC/MS) as previously described [36]. Intraday and
interday precision ranged from 1.2 to 4.1% and 2.5 to
5.3%, respectively. The calibration range was linear from
0.1 to 15 μg ml–1 and accuracy ranged from 95.2 to
104.6%. Several samples were obtained on the same
day from each participant. Sampling times were not
pre-specified, and time of prior dose was by self-report
for adults, and was reported by caregivers for children.
We excluded efavirenz data from samples obtained less
than 10 h or greater than 20 h post-dose, or before 1
month of efavirenz therapy, and from children within 1
month after discontinuing rifampicin. An average of mea-
sured concentrations was used when multiple samples
from the same participant were obtained. The repeated
measurements of efavirenz concentrations were used in
exploratory multilevel mixed effects (MLME) analyses.
Statistical analysis
The pharmacokinetic data were not normally distributed.
Therefore, a logarithmic (log10) transformation was done.
Genetic associations with log10 transformed average
efavirenz concentrations were analyzed by univariate lin-
ear regression. The tri-allelic ABCB1 rs2032582 was ana-
lyzed as A vs. not A, G vs. not G and T vs. not T. We also
performed analyses adjusting for CYP2B6 516G→T. All
tests used a 5% two-sided significance level. Analyses
were performed with PLINK version 1.07 (http://pngu.
mgh.harvard.edu/~purcell/plink/). Bonferroni correction
was used to account for multiple testing [37]. For polymor-
phisms previously associated with efavirenz pharmacoki-
netics, the threshold to carry forward into subsequent
linear regression models was P=0.01.
Haplotypic blocks were defined using the D’ confi-
dence intervals method in Haploview [38] and haplotype
phases were inferred using the standard E-M algorithm in
PLINK [39]. Linkage disequilibrium (LD) plots and values
were generated with Haploview (www.broad.mit.edu/
mpg/haploview/).
The multilevel mixed effect regression model per-
formed in Stata 11 [40], which accounted for within indi-
vidual correlations, evaluated associations of efavirenz
concentrations with the three polymorphisms adjusted
for effects of time post-dose and age group.
Results
Study participant characteristics
Pharmacokinetic data were available from 152 partici-
pants, of whom 113 with sufficient DNA for successful
genotyping are included in the present analyses. Among
59 adults, median age was 38 years (range 20 to 59 years),
median weight was 65.9 kg (range 45.2 to 104.5 kg) and
45 (76%) were female. Of participants with available
plasma HIV-1 RNA data, values were <400 copies ml–1
in 78% of adults and in 87% of children. Characteristics
of study participants are presented in Table 1.
Genetic polymorphisms
Among the 113 participants, 241 polymorphisms were
successfully genotyped, of which 18 were monomorphic
(i.e. no minor alleles). Each of the remaining 223 poly-
morphisms was in Hardy–Weinberg equilibrium based
on a Bonferroni adjusted P value threshold of 0.0002;
six had unadjusted P values <0.05 (NR1I3 rs4489574,
P = 0.002, NR1I2 rs2461817, P = 0.021, ABCB1 rs17149792,
P = 0.024, NR1I3 rs2502815, P = 0.026, ABCB1 rs10264990,
P = 0.035 and CYP3A4 rs28539499, P = 0.036). Minor allele
frequencies for the 241 polymorphisms are in Supplemen-
tal Material Table S1.
Genetic associations with efavirenz
concentrations
The median plasma mid-dose efavirenz concentration
was 2.03 μg ml–1 (interquartile range 1.46–3.46 μg ml–1).
In univariate linear regression models, composite CYP2B6
15582/516/983 genotype was most strongly associated
with efavirenz concentrations (β = 0.28, 95% CI 0.21,
0.35, P = 2.4 × 10–11). Of the 223 polymorphisms, 15 (all
in CYP2B6) were associated with efavirenz concentrations
at P<0.01. These include CYP2B6 516G→T (β = 0.22, 95%
CI 0.13, 0.30, P = 1.3x10–6) and eight polymorphisms in LD
with 516G→T at r2>0.6. The minor allele frequency of
CYP2B6 516G→T was 0.36, with 43 (38.1%) homozygous
for GG, 58 (51.3%) heterozygous for GT and 12 (10.6%) ho-
mozygous for TT. The minor allele frequency of CYP2B6
983T→C was 0.07, with 98 (86.7%) homozygous for TT,
Table 1
Demographic and clinical characteristics of 113 study participants in
South Africa.
Adults n Children n
Efavirenz concentration
(μg ml–1)*
2.63 (0.67–29.53) 59 1.90 (0.30–8.47) 54
Time after dose (h)* 12.3 (11.1–14.5) 59 16.2 (14.0–17.8) 54
Drug dose (mg day
–1
)* 600 (600–600) 59 300 (200–600) 54
Age (years)* 38.0 (20.0–59.0) 59 8.2 (3.0–15.1) 54
Weight (kg)* 65.9 (45.2–104.5) 59 22.3 (13.3–46.0) 54
Female gender† 45 (76.3) 59 25 (46.3) 54




290 (74–904) 59 533 (264–1522) 16




14 (77.8) 18 13 (86.7) 15
*Medians are shown (ranges in parentheses). †Numbers of patients are shown
(percentages in parentheses).
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15 (13.3%) heterozygous for TC and none homozygous
for CC. The minor allele frequency of CYP2B6 15582C→T
was 0.09, with 94 (83.2%) homozygous for CC, 18
(15.9%) heterozygous for TC and one (0.9%) homozygous
for TT.
To identify independent predictors of efavirenz con-
centrations we performed multivariable linear regression
analysis adjusted for CYP2B6 516G→T. By this analysis,
the only additional polymorphism associated at P< 0.01
was CYP2B6 983T→C (β=0.37, 95% CI 0.23, 0.52,
P=2.78 × 10-6). In an analysis that adjusted for both
CYP2B6 516G→T and 983T→C, no additional polymor-
phism was associated with efavirenz concentrations at
P<0.01, the lowest P value being for CYP2B6
rs28723610 (β = 0.21, 95% CI 0.04, 0.38, P = 0.013). There
was no apparent association with CYP2B6 15582C→T
(β=0.06, 95% CI –0.06, 0.19, P= 0.34). Final multivariable
linear regression models are presented in Table 2.
In the above analyses, two individuals had extreme
outlier efavirenz values. One individual, a 41-year-old
woman with a body mass index of 22 kg m–2, had three
concentrations of 28.1, 28.2 and 32.3 μg ml–1 (mean
29.30 μg ml–1). She was homozygous for 15582CC, 516GG
and 983TT. One individual, a 7-year-old boy weighing
21 kg at a height of 114 cm, had three concentrations of
0.32, 0.29 and 0.28 μg ml–1 (mean 0.30 μg ml–1). He was
heterozygous for 15582CT and homozygous for 516GG
and 983TT. To characterize associations with CYP2B6
15582C→T further, we performed post hoc sensitivity
analyses after censoring the two outliers. In such analyses,
adjusting for both 516G→T and 983T→C, fivemore CYP2B6
polymorphisms in weak LD with CYP2B6 516G→T showed
trends toward association with low efavirenz concentra-
tions in unadjusted analyses (Table 3), and CYP2B6
15582C→T was now associated with efavirenz concentra-
tions (β = 0.11, 95% CI 0.01, 0.22, P = 0.04) (Table 3).
Relationships between genotypes and efavirenz concentra-
tions in all individuals are presented in Figure 1A.
In the final multivariable model, each 516 T allele was
associated with a 31% increase in log10 efavirenz concen-
trations (β = 0.27, P<0.0001), each 983 C allele with a 46%
increase (β = 0.38, P<0.0001), and each 15582 T allele
with a 6% increase (β = 0.06, P = 0.340). These three poly-
morphisms explained 34% of variance in log10 efavirenz
concentrations. A model that included only CYP2B6
516G→T and 983T→C also explained 34% of variance
in log10 efavirenz concentrations. Univariate linear re-
gression models for each individual polymorphism ex-
plained 19%, 8% and only 0.59% of variance for CYP2B6
516G→T, 983T→C and 15582C→T, respectively.
In the post hoc sensitivity analysis that censored the
two outlier participants, each 516 T allele was associated
with a 33% increase in log10 efavirenz concentrations
(β=0.29, P<0.0001), each 983 C allele with a 48% in-
crease (β=0.39, P< 0.0001) and each 15582 T allele with
a 12% increase (β=0.12, P = 0.04), which together ex-
plained 45% of variance. A model that included only
CYP2B6 516G→T and 983T→C explained 43% of vari-
ance. Univariate linear regression models for each indi-
vidual polymorphism explained 24%, 10% and only
0.02% of variance for CYP2B6 516G→T, 983T→C and
15582C→T, respectively.
We also performed separate analyses among children
and adults. Linear regression results for children and
Table 2
Genetic associations with efavirenz concentrations in all 113 participants.
Unadjusted analysis 516G→T adjusted 516G→T and 983T→C adjusted
Chromosome Polymorphism β (95% CI) P value β (95% CI) P value β (95% CI) P value
19 CYP2B6 516G→T 0.22 (0.13, 0.30) 1.27 × 10
–6
NA NA NA NA
19 rs8192719 0.22 (0.13, 0.30) 1.27 × 10
–6
NA NA NA NA
19 rs2279343 0.22 (0.13, 0.30) 1.79 × 10
–6
NA NA NA NA
19 rs10853744 0.21 (0.13, 0.29) 2.33 × 10
–6
–0.13 (–0.70, 0.45) 0.66 –0.09 (–0.61, 0.43) 0.74
19 rs11083595 0.18 (0.10, 0.26) 2.30 × 10
–5
0.002 (–0.17, 0.17) 0.99 0.07 (–0.08, 0.23) 0.37
19 rs2054675 0.18 (0.10, 0.26) 2.30 × 10
–5
0.002 (–0.17, 0.17) 0.99 0.07 (–0.08, 0.23) 0.37
19 rs3786547 0.18 (0.10, 0.27) 2.39 × 10
–5
0.0001 (–0.17, 0.17) 1.00 0.07 (–0.09, 0.23) 0.38
19 rs892216 0.18 (0.09, 0.26) 6.71 × 10
–5
–0.006 (–0.16, 0.14) 0.93 0.05 (–0.09, 0.19) 0.49
19 rs7250873 0.16 (0.09, 0.25) 1.07 × 10
–4
–0.004 (–0.21, 0.11) 0.58 0.02 (–0.12, 0.17) 0.74
19 CYP2B6 983T→C 0.27 (0.10, 0.44) 1.92 × 10
–3
0.37 (0.22, 0.52) 2.78 × 10
-6
NA NA
19 rs1987236 –0.16 (–0.26, –0.05) 3.12 × 10
–3
–0.06 (–0.17, 0.04) 0.25 –0.02 (–0.12, 0.08) 0.68
19 rs4803417 –0.16 (–0.27, –0.05) 5.14 × 10
–3
–0.06 (–0.18, 0.05) 0.27 –0.03 (–0.13, 0.07) 0.58
19 rs2279345 –0.14 (–0.24, –0.03) 9.37 × 10
–3
–0.04 (–0.15, 0.06) 0.39 0.004 (–0.09, 0.10) 0.93
19 rs6508966 –0.14 (–0.24, –0.03) 9.37 × 10
–3
–0.04 (–0.15, 0.06) 0.39 0.004 (–0.09, 0.10) 0.93
19 rs6508965 –0.14 (–0.27, –0.05) 9.70 × 10
–3
–0.04 (–0.14, 0.06) 0.43 0.01 (–0.08, 0.11) 0.82
19 CYP2B6 15582C→T* –0.06 (–0.21, 0.08) 0.42 0.03 (–0.11, 0.17) 0.67 0.06 (–0.06, 0.19) 0.34
*SNP of interest but did not meet criteria of P value < 0.01.
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adults are shown in Supplemental Material Table S2 and
S3, respectively. In both analyses, CYP2B6 516G→T (and
polymorphisms in strong LD with CYP2B6 516G→T) and
983T→C were strongly associated with log10 efavirenz
concentrations. In unadjusted analyses, there was no as-
sociation with CYP2B6 15582C→T. In adults, unadjusted
analyses revealed that NR1I2 rs9847782 had the greatest
effect size (β = 0.37, 95% CI 0.11, 0.62, P = 7.3 × 10!3),
which was no longer apparent when one outlier was
excluded (a 41-year-old with very high efavirenz concen-
trations and homozygous for NR1I2 rs9847782TT). Inter-
estingly, in children only, when the outlier with an
exceptionally low log10 efavirenz concentration was ex-
cluded (a 7-year-old heterozygous for CYP2B6 15582 CT),
CYP2B6 15582C→T showed a trend towards signifi-
cance when adjusted for CYP2B6 516G→T and
983T→C (β=0.08, 95% CI 0.005, 0.30, P = 0.05). Rela-
tionships between genotypes and efavirenz concentra-
tions in children and adults are presented in Figure 1B
and Figure 1C, respectively.
As there were clinical differences (including age and
sampling time post-dose) between adults and children
in our analyses, we explored multilevel mixed effects
modelling using each measured efavirenz value sepa-
rately in each participant, rather than the mean of con-
centration values. We fitted a hierarchical model that
predicted log10 efavirenz concentrations as a function
of 1) fixed effects of age group, time after dose, CYP2B6
516G→T, 983T→C and 15582C→T and 2) random ef-
fects for the individual to account for within individual
correlations. In this model, compared with individuals
in the lowest concentration stratum (i.e. 15582CC-
516GG-983TT, β = 0.58), when time after dose and age
group were held constant, homozygosity for CYP2B6
516TT was associated with an 0.64 increase in log10
efavirenz concentrations (2.9-fold increase in measured
efavirenz concentrations), heterozygosity for CYP2B6
983TC with an 0.36 increase in log10 efavirenz concen-
trations (2.1-fold increase in measured efavirenz con-
centrations), heterozygosity for CYP2B6 516GT with an
0.19 increase in log10 efavirenz concentrations (1.5-fold
increase in measured concentrations), homozygosity
for CYP2B6 15582TT with an 0.21 increase in log10
efavirenz concentrations (1.4-fold increase in measured
efavirenz concentrations) and heterozygosity for
CYP2B6 15582CT with an 0.06 increase in log10 efavirenz
concentrations (1.2-fold increase in measured efavirenz
concentrations).
Linkage disequilibrium between CYP2B6
polymorphisms
To understand relationships between CYP2B6 polymor-
phisms associated with efavirenz concentrations better,
we considered LD. In the first model, without adjusting
Table 3
Genetic associations with log10-transformed efavirenz concentrations in all 111 participants, and excluding two outliers.
Unadjusted analysis 516G→T adjusted 516G→T and 983T→C adjusted
Chromosome Polymorphism β (95% CI) P value β (95% CI) P value β (95% CI) P value
19 CYP2B6 516G→T 0.23 (0.15, 0.30) 3.83 × 10
–8
NA NA NA NA
19 rs8192719 0.23 (0.15, 0.30) 3.83 × 10
–8
NA NA NA NA
19 rs2279343 0.22 (0.15, 0.30) 4.33 × 10
–8
NA NA NA NA
19 rs10853744 0.22 (0.14, 0.29) 8.64 × 10
–8
–0.13 (–0.64, 0.38) 0.63 –0.08 (–0.53, 0.36) 0.71
19 rs11083595 0.17 (0.09, 0.24) 2.84 × 10
–5
–0.11 (–0.26, 0.04) 0.17 –0.04 (–0.18, 0.10) 0.57
19 rs2054675 0.17 (0.09, 0.24) 2.84 × 10
–5
–0.11 (–0.26, 0.04) 0.17 –0.04 (–0.18, 0.10) 0.57
19 rs3786547 0.17 (0.09, 0.24) 2.94 × 10
–5
–0.11 (–0.27, 0.04) 0.16 –0.04 (–0.18, 0.10) 0.56
19 rs892216 0.16 (0.08, 0.24) 9.04 × 10
–5
–0.09 (–0.22, 0.05) 0.20 –0.03 (–0.15, 0.09) 0.58
19 rs7250873 0.15 (0.08, 0.23) 1.47 × 10
–4
–0.14 (–0.29, 0.0008) 0.05 –0.08 (–0.20, 0.05) 0.25
19 CYP2B6 983T→C 0.28 (0.12, 0.43) 6.10 × 10
–4
0.38 (0.26, 0.51) 3.13 × 10
!8
NA NA
19 rs6508950 –0.14 (–0.23, –0.06) 1.28 × 10
–3
–0.10 (–0.17, –0.02) 0.02 –0.05 (–0.12, 0.02) 0.14
19 rs1987236 –0.15 (–0.25, –0.06) 1.35 × 10
–3
–0.05 (–0.14, 0.04) 0.28 –0.004 (–0.09, 0.08) 0.93
19 rs4803417 –0.16 (–0.26, –0.06) 2.43 × 10
–3
–0.05 (–0.15, 0.05) 0.30 –0.01 (–0.10, 0.08) 076
19 rs10422346 –0.16 (–0.26, –0.05) 3.58 × 10
–3
–0.06 (–0.16, 0.04) 0.27 –0.03 (–0.13, 0.07) 0.58
19 rs2279345 –0.13 (–0.23, –0.04) 4.98 × 10
–3
–0.03 (–0.13, 0.06) 0.46 0.02 (–0.06, 0.10) 0.60
19 rs6508966 –0.13 (–0.23, –0.04) 4.98 × 10
–3
–0.03 (–0.13, 0.06) 0.46 0.02 (–0.06, 0.10) 0.60
19 rs6508965 –0.13 (–0.23, –0.04) 5.20 × 10
–3
–0.03 (–0.12, 0.06) 0.53 0.03 (–0.05, 0.11) 0.47
19 rs7259758 –0.14 (–0.25, –0.04) 5.47 × 10
–3
–0.06 (–0.16, 0.04) 0.25 –0.02 (–0.11, 0.06) 0.64
19 rs1962261 –0.15 (–0.26, –0.04) 6.27 × 10
–3
–0.06 (–0.16, 0.04) 0.23 –0.02 (–0.12, 0.02) 0.60
19 rs11671243 –0.12 (–0.22, –0.03) 9.16 × 10
–3
–0.02 (–0.11, 0.07) 0.68 0.02 (–0.06, 0.10) 0.55
19 CYP2B6 15582C→T* –0.01 (–0.15, 0.13) 0.87 0.08 (–0.04, 0.21) 0.18 0.12 (0.01, 0.22) 0.04
*SNP of interest, did not meet criteria of P value < 0.01.
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for any polymorphisms, two groups of polymorphisms
were associated with efavirenz concentrations (Table 2),
the first comprising eight polymorphisms in strong LD
with CYP2B6 516G→T and with minor alleles associated
with higher efavirenz concentrations (i.e. positive β
values), and the second comprising five polymorphisms
in weaker LD with CYP2B6 516G→T and with minor
alleles trending towards an association with lower
efavirenz concentrations (i.e. negative β values). In the
second analyses, which adjusted for CYP2B6 516G→T,
none of the above 13 polymorphisms remained associ-
ated with efavirenz concentrations, with only CYP2B6
983T→C becoming significant, with a greater effect size
and even lower P value (Table 2). No polymorphisms
were in strong LD with CYP2B6 983T→C. In the third anal-
yses, which adjusted for CYP2B6 516G→T and 983T→C,
no other polymorphisms were associated with efavirenz
concentrations (Table 2). Linkage disequilibrium be-
tween the CYP2B6 polymorphisms is shown in Figure 2.
We only show polymorphisms with P values < 0.01 on
unadjusted analyses, as well as CYP2B6 15582C→T and
CYP2B6 -2320T→C (rs7251950) polymorphisms. The lat-
ter was included because it was reported to be in strong
LD with CYP2B6 15582C→T in other populations [26]. In
our cohort, it was in weak LD with CYP2B6 15582C→T
(r2 =0.19).
Previously reported associations beyond CYP2B6
Polymorphisms in genes beyond CYP2B6 reported to af-
fect efavirenz pharmacokinetics include ABCB1 [12, 41],
CYP2A6 [7, 30], CYP3A5 [2], UGT2B7 [7] and CAR [42, 43].
Univariate and multivariate analyses revealed no associa-
tions beyond CYP2B6 and the results are shown in
Supplemental Material Table S4. The minor allele frequen-
cies are also displayed. The CYP2A6 rs1801272 was mono-
morphic in our cohort. With only 18 participants with
CYP2B6 slow metabolizer genotypes, we were unable to
replicate a previously reported association with CYP2A6 -
48T→G (rs28399433) in this group (P = 0.89).
Discussion
Efavirenz is one of the most extensively prescribed
medications worldwide for HIV-1 infection, and multiple
previous studies have associated CYP2B6 516 G→T
[2–13] and CYP2B6 983 T→C [9, 13, 16, 21–25], with
increased plasma efavirenz concentrations. Our study
replicated these associations in Black South Africans.
In addition, we showed for the first time that CYP2B6
15582C→T was associated with plasma efavirenz con-
centrations in Black South Africans, which had previ-
ously only been reported for efavirenz in one study
from the United States [26]. In univariate analyses, a
model that included composite genotype best pre-
dicted efavirenz concentrations. These associations
Figure 1
Relationships between CYP2B6 polymorphisms and log10 transformed
efavirenz concentrations in adults and children. Efavirenz concentra-
tions were determined as described in Methods. Relationships with
CYP2B6 polymorphisms and log10 efavirenz concentrations are shown
in all participants (A), adults (B) and children (C). On the x-axis, CYP2B6
haplotypes represent (in order) CYP2B6 15582C→T (CC, CT, TT),
516G→T (GG, GT, TT) and 983T→C (TT, TC). Number per CYP2B6 haplo-
type is also displayed. On the y-axis, the log10 transformed efavirenz
concentrations are displayed. On each graph, each marker represents
a different participant. Horizontal bars are medians and interquartile
ranges. Median values are above
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were consistent in adults and children. An association
between CYP2B6 15582C→T and slower plasma drug
clearance has also been reported among Cambodians
for the CYP2B6 substrate nevirapine [44], further
supporting the validity of our finding. We did not
find significant associations beyond CYP2B6 516G→T,
983T→C and 15582C→T. Although one analysis suggested
an association with NR1I2 rs9847782, this was no longer
apparent after excluding one outlier, suggesting a spuri-
ous association. Our study also provided information
regarding minor allele frequencies for ABCB1, CYP2A6,
CYP2B6, CYP3A4, NR1I2 and NR1I3 polymorphisms in a
South African population.
We observed somewhat lower efavirenz concentra-
tions in children, which is probably explained by the
higher clearance in children compared with adults rela-
tive to their size [45]. Although WHO weight-based dos-
ing in children is intended to achieve efavirenz
concentrations similar to those in adults with fixed dos-
ing, high prevalence of low efavirenz concentrations in
children has been observed in a South African popula-
tion similar to ours, and has been attributed to the
current weight based WHO guidelines [46]. We assessed
associations between polymorphisms and efavirenz con-
centrations separately in adults and children. In both
children and adults, CYP2B6 516G→T had the strongest
overall association with efavirenz concentrations, al-
though CYP2B6 983T→C had the greatest effect size per
allele. The association with CYP2B6 15582C→T could
not be demonstrated in adults and children analyzed
separately, possibly due to smaller samples sizes.
In the present analysis, minor allele frequencies of
CYP2B6 516G→T, 983T→C, and 15882C→T were 0.36,
0.07 and 0.09, respectively. In the multivariate regression
model including all three polymorphisms, CYP2B6
983T→C had the greatest magnitude of effect on log10
efavirenz concentrations (β=0.38 for 983T→C, β=0.27
for 516G→T, β = 0.06 for 15882C→T), but due to lower
frequency only explained approximately 8% of variance
in univariate analysis vs. 19% for 516G→T, and negligible
effect for 15882C→T. In sensitivity analyses that ex-
cluded two individuals with extreme outlier efavirenz
concentrations, the variance explained by all three poly-
morphisms increased from 34% to 45%.
Figure 2
Linkage disequilibrium plot between polymorphisms in the CYP2B6 locus created in Haploview. Data from all 113 participants are included. Black de-
notes r2 = 1, shades of grey, 0 < r2< 1, white, r2 = 0. Only polymorphisms with P values <0.01 on unadjusted analyses, as well as CYP2B6 15582C→T
and CYP2B6 -2320T→C (rs7251950) polymorphisms are shown. r2 is displayed to show LD
P. Z. Sinxadi et al.
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Our analyses included two participants with extreme
outlier efavirenz concentrations, and in neither of the
cases could we identify an explanation. Dose-to-sampling
times were reported to be within the 10–20 hmid-dose in-
terval window and there were multiple efavirenz determi-
nations from each participant. However, non-adherence
in the participant with the lowest concentrations cannot
be excluded. Sensitivity analyses that excluded these
two participants allowed a significant association be-
tween CYP2B6 15882C→T and log10 efavirenz concentra-
tions to be demonstrated. This same approach to censor
outliers was used by Bertrand et al. [44] and highlights
the critical importance of minimizing phenotype misclas-
sification for detecting true associations.
Our primary analyses considered genetic associations
with log10-transformed efavirenz concentrations. Where
data frommultiple samples were available from the same
individual, the time adjusted average was used. We also
employed the hierarchical model to consider repeated
measurements taking into account variation on fixed
(CYP2B6 516G→T, 983T→C and 15582 C→T genotypes,
age group, time after dose) and random (individual) ef-
fects. The advantage of this analysis is that it provides
more information about the contribution of genotype
to the increase in efavirenz concentrations when all other
parameters are equal.
Previous studies from Africa have replicated the asso-
ciation between CYP2B6 516G→T and plasma efavirenz
exposure, including studies of patients from Zimbabwe
[8, 9, 13], South Africa [10, 11, 17, 25], Ghana [7, 24],
Uganda [12, 13], Tanzania [14, 15], Rwanda [16] and Ethiopia
[14]. Multiple studies of patients from Africa have also
shown the association with 983T→C [9, 13, 16, 21, 24, 25].
Data for association beyond CYP2B6 are limited. A study of
patients in Ghana found associations with CYP2A6 and
UGT2B7 polymorphisms [7], but a subsequent study of pa-
tients in Ghana did not replicate independent associations
with these polymorphisms [24].
The association between CYP2B6 15582C→T and
plasma efavirenz concentrations was first discovered
and replicated in a genome-wide association study from
the United States [26]. This polymorphism was also asso-
ciated with increased plasma efavirenz concentrations in
Cambodians receiving concomitant antituberculosis
therapy with isoniazid and rifampicin [47]. In Cambo-
dians receiving nevirapine, CYP2B6 15582C→T was also
associated with decreased plasma nevirapine clearance,
as was CYP2B6 -2320T→C (rs7251950), which was in
strong LD with CYP2B6 15582C→T in that study [44]. In
contrast, in the present study CYP2B6 -2320T→C was in
weak LD with 15582C→T (r2 = 0.19) and was not associ-
ated with efavirenz concentrations. In addition, Lamba
et al. reported that CYP2B6 15582C→T was associated
with lower hepatic CYP2B6 expression in females [48].
In the present study, while the association with CYP2B6
15582C→T was only significant in analyses that included
both adults and children and with outliers excluded (to
provide a cleaner phenotype), this association was highly
likely to be valid considering the above reports in non-
African populations. Additional studies on other popula-
tions will help to replicate and refine this association
further.
This study increases our understanding of efavirenz
pharmacogenetics and has potential clinical implica-
tions. Because many patients (especially those with inter-
mediate and slow metabolizer CYP2B6 genotypes) have
plasma efavirenz exposure in considerable excess of
what is needed to control HIV-1 replication, there has
been interest in alternative dosing strategies for
efavirenz. The ENCORE1 study evaluated routinely initiat-
ing a lower dose of efavirenz (400 mg rather than 600
mg) in adults without genetic testing, and showed some-
what improved tolerability and no apparent loss of anti-
viral efficacy [49]. If that approach is to be translated
into clinical practice, the present study suggests that
the group at greatest risk for subtherapeutic efavirenz
concentrations will be patients who lack polymorphisms
at all three loci (i.e. CYP2B6 516GG-983TT-15582CC). Only
by genotyping for all three polymorphism can this group
be defined. Consideration has also been given to using
genetic testing to individualize better efavirenz dosing.
This may be most practical in paediatrics, where individ-
ualized weight-based dosing is already used. In this set-
ting, testing for polymorphisms at all three loci will
allow the most precise dosing.
The present study considered combined analyses in-
volving both adults and children, as well as subgroup
analyses involving adults and children separately. A po-
tential concern with combined analyses is the different
approach to dosing efavirenz, with adults receiving a uni-
form dose and children receiving a weight-based dose,
which might offset the advantage of a larger sample size.
Several considerations provided reassurance that com-
bined analyses were not problematic, and improved our
likelihood of finding true associations. First, associations
with the known loss-of-function polymorphisms, CYP2B6
516G→T and 983T→C, were far more significant in com-
bined analyses than in subgroup analyses, suggesting
that our ability to detect true associations was increased,
not decreased, by combining groups. Second, the associ-
ation with CYP2B6 15582C→T only achieved significance
in combined analyses. Third, the rationale for a weight-
based dose in children was to approximate plasma expo-
sure in adults, which reduces concern about combining
groups.
There were limitations to the present study. Sample
size limited our power to identify novel genetic associa-
tions for polymorphisms that were infrequent or had
small effects, even with the dataset that included both
adults and children. For example, assuming a standard
deviation of 0.33 for log10 efavirenz concentration within
each genotype group and a type II error of 0.2, we have
Efavirenz pharmacokinetics in Cape Town
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80% power for the following differences in pair-wise
means homozygotes and heterozygotes: with 59 sub-
jects and MAF = 0.1 a difference of 0.24 log10 (~75% ab-
solute), with 59 subjects and MAF = 0.3 a difference
0.19 log10 (~55% absolute), with 113 subjects and
MAF = 0.1 a difference of 0.17 log10 (~50% absolute), with
113 subjects and MAF = 0.3 a difference of 0.14 log10
(~40% absolute). Small sample size also limited our ability
to test for interactions between CYP2B6 genotype and
age in children, although we did not anticipate such inter-
actions. Because the dose of efavirenz was not observed,
we could not be certain of dose sampling times.
In summary, the present study improves the under-
standing of genetic determinants of efavirenz plasma ex-
posure in an African population, including adults and
children. Studies of associations between efavirenz con-
centrations and polymorphisms in African populations
should consider CYP2B6 516G→T and 983T→C, and ide-
ally also 15582C→T.
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Supplemental Table S2. Genetic associations with log10-transformed efavirenz concentrations 
in 54 South African children. 
 
 
  Unadjusted analysis 516G→T adjusted 516G→T & 983T→C adjusted 
Chromosome Polymorphism β(95%CI) P-value β(95%CI) P-value β(95%CI) P-value 
19 rs2279343 0.25(0.13-0.37) 1.61 x10-04 NA NA NA NA 
19 CYP2B6 516G→T 0.24(0.12-0.37) 2.10 x10-04 NA NA NA NA 
19 rs8192719 0.24(0.12-0.37) 2.10 x10-04 NA NA NA NA 
19 rs10853744 0.23(0.11-0.34) 3.67 x10-04 -0.04(-0.57 to 0.48) 0.87 -0.01(-0.45 to 0.45) 0.96 
19 rs892216 0.17(0.06-0.28) 4.61 x10-03 -0.02(-0.20 to 0.17) 0.85 0.04(-0.12 to 0.21) 0.59 
19 rs3760657 -0.83(-1.38 to -0.27) 4.74 x10-03 -0.67(-1.17 to -0.16) 0.01 -0.59(-1.03 to -0.16) 0.01 
19 rs4802100 -0.83(-1.38 to -0.27) 4.74 x10-03 -0.67(-1.17 to -0.16) 0.01 -0.59(-1.03 to -0.16) 0.01 
19 rs34128717  -0.28(-0.47 to -0.08) 6.74 x10-03 -0.19(-0.37 to -0.01) 0.05 -0.11(-0.29 to 0.05) 0.17 
19 rs11083595 0.16(0.04-0.27) 8.33 x10-03 0.11(-0.32 to 1.00) 0.31 -0.06(-0.24 to 0.12) 0.52 
19 rs2054675 0.16(0.04-0.27) 8.33 x10-03 0.11(-0.32 to 1.00) 0.31 -0.06(-0.24 to 0.12) 0.52 
19 rs3786547 0.16(0.04-0.27) 8.94 x10-03 -0.11(-0.32 to 1.00) 0.30 0.07(-0.09 to 0.23) 0.38 
19 rs1962261 -0.26(-0.44 to -0.07) 9.86 x10-03 -0.17(-0.35 to 0.003) 0.05 -0.11(-0.27 to 0.05) 0.18 
19 CYP2B6 983T→C 0.36(0.09-0.62) 9.97 x10-03 0.46(0.25-0.68) 9.77 x10-05 NA NA 
19 CYP2B6 15582C→T* 0.02(-0.18 to 0.21) 0.88 0.11(-0.07 to 0.29) 0.23 0.07(-0.08 to 0.23) 0.38 
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Supplemental Table S3. Genetic associations with log10-transformed efavirenz concentrations 
in 59 South African adults. 
  Unadjusted analysis 516G→T adjusted 516G→T & 983T→C adjusted 
Chromosome Polymorphism β(95%CI) P-value β(95%CI) P-value β(95%CI) P-value 
19 rs11083595 0.22(0.11-0.33) 2.41 x10-04 0.16(-0.10 to 0.41) 0.23 0.24(0.004-0.49) 0.05 
19 rs2054675 0.22(0.11-0.33) 2.41 x10-04 0.16(-0.10 to 0.41) 0.23 0.24(0.004-0.49) 0.05 
19 rs3786547 0.22(0.11-0.33) 2.41 x10-04 0.16(-0.10 to 0.41) 0.23 0.24(0.004-0.49) 0.05 
19 CYP2B6 516G→T 0.20(0.10-0.31) 4.49 x10-04 NA NA NA NA 
19 rs8192719 0.20(0.10-0.31) 4.49 x10-04 NA NA NA NA 
19 rs10853744 0.20(0.10-0.31) 4.49 x10-04 NA NA NA NA 
19 rs2279343 0.20(0.09-0.31) 6.57 x10-04 NA NA NA NA 
19 rs7250873 0.20(0.10-0.31) 8.09 x10-04 0.07(-0.17 to 0.31) 0.58 0.15(-0.08 to 0.38) 0.21 
19 rs892216 0.20(0.10-0.31) 1.50 x10-03 0.04(-0.20 to 0.28) 0.73 0.09(-0.14 to 0.31) 0.45 
3 rs9847782 0.37(0.11-0.62) 7.30 x10-03 0.28(0.03 to 0.52) 0.03 0.32(0.09 to 0.55) 8.05 x10-03 
19 CYP2B6 983T→C* 0.19(0.03-0.40) 9.17 x10-02 0.27(0.09-0.47) 6.21 x10-03 NA NA 
19 CYP2B6 15582C→T* -0.11(-0.31 to 0.10) 0.31 -0.17(-0.21 to 0.18) 0.90 0.05(-0.13 to 0.24) 0.58 
     *SNP of interest but did not meet criteria of p-value<0.01 
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Supplemental Table S4. Genetic polymorphisms beyond CYP2B6 and association with log10- 












Unadjusted analysis 516G→T, 983T→C & 15582C→T adjusted 
β(95%CI) P-value β(95%CI) P-value 
1 CAR rs2307424 (T) 0.06 -0.03(-0.22 – 0.15) 0.74 0.08(-0.07 – 0.24) 0.31 
1 CAR rs2502815 (T) 0.22 -0.01(-0.11 – 0.07) 0.70 -0.08(-0.08 – 0.07) 0.84 
1 CAR rs3003596 (G) 0.40 -0.01(-0.04 – 0.07) 0.76 -0.02(-0.09 – 0.05) 0.54 
7 ABCB1 rs3842 (G) 0.25 0.02(-0.08 – 0.12) 0.74 -0.01(-0.10 – 0.08) 0.79 
7 ABCB1 rs1045642 (T) 0.13 0.10(-0.02 – 0.22) 0.10 0.10(-0.004 – 0.20) 0.06 
7 ABCB1 rs2032582 (T/G/A) 0.02 0.24(-0.08 – 0.56) 0.14 0.28(0.13 – 0.54) 0.04 
7 ABCB1 rs1128503 (T) 0.13 -0.01(-0.14 – 0.12) 0.87 0.01(-0.09 – 0.10) 0.89 
7 CYP3A4 rs2740574 (A) 0.23 0.05(-0.06 – 0.09) 0.40 0.02(-0.08 – 0.11) 0.73 
7 CYP3A4 rs4646437 (C) 0.12 0.01(-0.12 – 0.12) 0.87 0.01(-0.10 – 0.12) 0.85 
7 CYP3A5 rs776746 (G) 0.14 0.01(-0.13 – 0.12) 0.99 -0.04(-0.14 – 0.08) 0.48 
10 CYP2C19 rs4244285 (A) 0.20 0.01(-0.10 – 0.12) 0.85 0.01(-0.10 – 0.12) 0.85 
19 CYP2A6 rs28399433 (G) 0.07 0.17(0.001 – 0.35) 0.05 0.11(-0.03 – 0.26) 0.13 
19 CYP2A6 rs28399454 (A) 0.06 -0.13(0.31 – 0.04) 0.15 -0.01(-0.16 – 0.14) 0.88 
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Plasma efavirenz concentrations are associated with lipid and glucose concentrations  
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Efavirenz-based antiretroviral therapy (ART) has been associated with dyslipidaemia and 40"
dysglycaemia, risk factors for cardiovascular disease. However, the pathogenesis is not well 41"
understood. We characterized relationships between plasma efavirenz concentrations and lipid and 42"
glucose concentrations in HIV-infected South Africans. 43"
METHODS: 44"
Participants on efavirenz-based ART were enrolled into a cross-sectional study. Oral glucose tolerance 45"
test was performed after an overnight fast, and plasma drawn for mid-dosing interval efavirenz, fasting 46"
total cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, and 47"
triglycerides concentrations.  48"
RESULTS: 49"
Among 106 participants (77 women), median age was 38 years, median CD4+ T-cell count was 322 50"
cells/µL, median duration on ART was 18 months, and median (interquartile range) efavirenz 51"
concentration was 2.23 (1.66 to 4.10) µg/mL. On multivariable analyses (adjusting for age, sex, body 52"
mass index, and ART duration) doubling of efavirenz concentrations resulted in mean changes in 53"
mmol/L (95%CI) of: total cholesterol [0.40 (0.22 to 0.59)], LDL cholesterol [0.19 (0.04 to 0.30)], HDL 54"
cholesterol [0.14 (0.07 to 0.20)], triglycerides [0.17 (0.03 to 0.33)], fasting glucose [0.18 (0.03 to 55"
0.33)], and 2-hour glucose concentrations [0.33 (0.08 to 0.60)].  Among 57 participants with CYP2B6 56"
genotype data, associations between slow metabolizer genotypes and metabolic profiles were generally 57"
consistent with those for measured efavirenz concentrations. 58"
 59"
CONCLUSIONS: 60"
Higher plasma efavirenz concentrations are associated with higher plasma lipid and glucose 61"
concentrations. This may have implications for long-term cardiovascular complications of efavirenz-62"
based ART, particularly among populations with high prevalence of CYP2B6 slow metabolizer 63"
genotypes.  64"
 65"
Keywords: efavirenz pharmacokinetics, LDL cholesterol, HDL cholesterol, triglycerides, glucose, 66"





The non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz is extensively prescribed and is 70"
included in the World Health Organization’s preferred first-line ART regimens for HIV-1 infected 71"
adults, adolescents and children at least 3 years of age.1 Efavirenz-based ART has been associated with 72"
the development of dysglycaemia2 and dyslipidaemia;3-5 specifically increases in total cholesterol: 73"
HDL cholesterol ratio, LDL cholesterol, and triglycerides.6,7 The pathogenesis of these metabolic 74"
effects are unclear, although it has been suggested that efavirenz may contribute to mitochondrial 75"
toxicity caused by concomitant thymidine analogue nucleoside reverse transcriptase inhibitors (NRTI).8 76"
 77"
Data are scant regarding relationships between plasma efavirenz concentrations and plasma glucose or 78"
lipid concentrations. There is considerable interindividual variability in plasma efavirenz exposure, 79"
which is largely explained by three CYP2B6 loss-of-function polymorphisms.9,10 The two 80"
polymorphisms with the greatest effect, CYP2B6 516G→T and CYP2B6 983T→C, are particularly 81"
frequent with African ancestry.11,12 The CYP2B6 516G→T polymorphism is also frequent in Thai and 82"
Cambodian populations.13,14 83"
 84"
We investigated whether plasma efavirenz concentrations correlated with plasma lipid and/or glucose 85"
concentrations in HIV-infected South Africans. We hypothesized that higher plasma efavirenz 86"
concentrations would be associated with higher lipid and glucose concentrations. 87"
 88"
MATERIALS AND METHODS 89"
Study design and participants 90"
 We conducted a prospective cross-sectional study of consecutive HIV-infected African adults who 91"
presented for routine follow up visits at one community-based (Crossroads) and one hospital-based 92"
(Groote Schuur) ART clinic in Cape Town, South Africa. Participants were recruited by convenient 93"
sampling between February 2007 and September 2008. South African ART guidelines at the time of 94"
this study recommended an NNRTI plus two NRTIs (stavudine or zidovudine, each with lamivudine) 95"
as first-line therapy. Eligible participants were on efavirenz-based ART for at least six months. 96"
Exclusion criteria included pregnancy, renal or hepatic disease, active opportunistic infections, 97"
treatment for diabetes or dyslipidaemia, and self-reported non-adherence. The study was conducted in 98"
accordance with the Declaration of Helsinki and the South African Good Clinical Practice. The 99"
University of Cape Town Research Ethics Committee approved the study (REC REF 128/2007). All 100"
participants gave written informed consent.   101"
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Clinical and laboratory evaluations 102"
Participants were instructed to fast overnight and to document the time of the evening dose of efavirenz 103"
on the day preceding the study visit. On the study day, participants underwent an oral glucose tolerance 104"
test (OGTT). Blood was drawn at 0 and 120 minutes after ingesting 75 g of glucose in 250 mL of 105"
water, and kept on ice until centrifuged within 4 hours. Plasma for efavirenz quantification was 106"
collected into 4mL lithium heparin tubes, kept on ice until centrifuged within 4 hours, and was 107"
aliquotted and promptly frozen at −20°C, then stored at -70°C until analysis at the end of recruitment in 108"
2008. Plasma efavirenz, fasting glucose, cholesterol, and triglyceride were quantified using the 0 109"
minute OGTT samples.  110"
Efavirenz was quantified by a validated method using liquid chromatography-tandem mass 111"
spectrometry (LC-MS/MS) on an Applied Biosystems MDS Sciex API 4000 tandem mass 112"
spectrometer at our ISO17025 compliant and accredited analytical laboratory as previously described.15 113"
The assay range of quantification was 0.05 to 20 µg/mL. Accuracy ranged from 94 to 103%. Serum 114"
glucose and lipid concentrations were determined by standard methods using the ACE Alera Clinical 115"
Chemistry System (Alfa Wassermann Diagnostic Technologies, Woerden, Netherlands). Diabetes, 116"
impaired fasting glucose, and impaired glucose tolerance were defined according to American Diabetes 117"
Association criteria.16 Hypercholesterolaemia, high LDL cholesterol, low or high HDL, and 118"
hypertriglyceridaemia were defined according to the NCEP III criteria.17  119"
Medical records were reviewed to determine duration on ART, plasma HIV-1 RNA concentrations, and 120"
CD4+ T-cell counts. Baseline CD4+ T-cell counts were recorded, and current CD4+ T-cell count was 121"
defined as the most recent value within 3 months of enrolment. Adherence was assessed using a 122"
validated 4-day adherence questionnaire administered by trained staff.18  123"
Pharmacokinetic and statistical analysis  124"
Medians (interquartile ranges) and proportions or ratios were used to describe continuous and 125"
categorical data, respectively. Scatter plots to visualize relationships between plasma efavirenz 126"
concentrations and metabolic parameters were generated using Prism version 6 (GraphPad Software, 127"
Inc., La Jolla, California, USA). Plasma efavirenz concentrations were log10 transformed to 128"
approximate normality. Associations between log10 transformed plasma efavirenz concentrations and 129"
cholesterol, triglycerides, and glucose were determined using univariate and multivariate linear 130"
regression analyses on Stata (version 11, StataCorp, College Station, Texas, USA). Univariate linear 131"
regression analyses characterized associations between log10 transformed association as a independent 132"
variable, and several dependent variables: fasting total cholesterol, LDL cholesterol, HDL cholesterol, 133"
triglycerides, glucose, and 2-hour OGTT glucose. Multivariate linear regression analyses adjusted for 134"
age, sex, body mass index (BMI) and total duration on ART. These potential confounders were chosen 135"
a priori. Sensitivity analyses included adjusting for current stavudine use. Case sensitivity analyses 136"
with the participant with the highest plasma concentrations were done. Missing data were not imputed.   137"
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In a subset of participants with available CYP2B6 genotype data, we explored relationships between 138"
CYP2B6 polymorphisms known to predict increased plasma efavirenz concentrations, CYP2B6 139"
516G>T (rs3745274), 983T>C (rs28399499) and 15582C>T (rs4803419), and metabolic parameters 140"
using linear regression in PLINK.19 We did not correct for multiple comparisons. Genotyping was done 141"
in the Vanderbilt DNA Resources Core as described elsewhere.20 Composite 516/983 or 142"
15582/516/983 genotypes were as assigned as previously described.20 143"
 144"
RESULTS 145"
107 participants were recruited into the study.  One participant with an efavirenz concentration below 146"
the limit of assay quantification was excluded from analyses for presumed non-adherence. 147"
Characteristics of the 106 evaluable participants are provided in Table 1. All participants were black 148"
Africans and most were women, reflecting the patient population at these clinics. More than 90% had 149"
been exposed to stavudine. All participants reported 100% adherence. Only 34 participants had plasma 150"
HIV-1 RNA data available within the previous 3 months. Metabolic abnormalities, as defined by 151"
NCEP III and ADA criteria, were common: hypercholesterolaemia was present in 40%, 152"
hypertriglyceridaemia in 26%, low HDL cholesterol in 49%, high LDL cholesterol in 42%, impaired 153"
fasting glucose in 24%, impaired glucose tolerance in 10%, and diabetes in 2%.  154"
The median efavirenz concentration was 2.23 µg/mL (IQR 1.66 to 4.10 µg/mL). Median time after the 155"
last dose was 12.08 hours (IQR 11.62 to 12.78 hours). Relationships between plasma efavirenz 156"
concentrations and metabolic parameters are shown in Figure 1. There was a positive correlation 157"
between higher log10 transformed efavirenz concentrations and higher fasting total cholesterol, HDL 158"
cholesterol, LDL cholesterol concentrations, but not with triglycerides and 2-hour OGTT glucose 159"
concentrations. There was a non-significant correlation between plasma efavirenz concentrations and 160"
fasting glucose concentrations (p = 0.073). 161"
In multivariate analyses that adjusted for age, sex, BMI, and duration on ART, log10 transformed 162"
efavirenz concentrations were independently associated with both lipid and glucose concentrations as 163"
displayed in Table 2. Table 2 also shows the mean change in each metabolic parameter per doubling 164"
of efavirenz concentrations. In these multivariate analyses, advancing age was also independently 165"
associated with increasing cholesterol (total cholesterol, HDL and LDL cholesterol) and glucose 166"
(fasting and 2 hour), but not triglycerides (data not shown). When current stavudine use was included 167"
in the multivariate model with age, sex, BMI, and total duration on ART, similar associations between 168"
the log10 transformed efavirenz concentrations and both lipid and glucose concentrations were found 169"
(see Table, Supplementary Digital Content 1, a table that illustrates the multivariate regression 170"
analyses adjusting for age, sex, BMI, total duration on ART, and current stavudine use). Current 171"
stavudine use was not included in the final model because it was not a significant variable in all models 172"
(data not shown).  173"
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In the final multivariate regression model that included log10 transformed efavirenz concentrations, age, 174"
sex, BMI, and total duration on ART, the log10 transformed efavirenz concentrations explained 26% of 175"
interindividual variability for total cholesterol, 23% for HDL cholesterol, 20% for triglycerides, 19% 176"
for 2-hour glucose, 17% for fasting glucose, and 16% for LDL cholesterol. 177"
Exploratory analysis examined relationships between CYP2B6 genotypes and metabolic parameters 178"
among 57 participants with available genotype data. Allelic frequencies of CYP2B6 516G→T, 179"
983T→C, and 15582C→T were 0.35, 0.08, and 0.08, respectively. Genotype frequencies are displayed 180"
in Supplemental Digital Content 2 (see figure, Supplemental Figure 1, that illustrates a bar graph 181"
displaying CYP2B6 genotype frequencies in 57 South African adults). There was a significant 182"
association between CYP2B6 516G→T and total cholesterol concentrations (p = 0.048) as shown in 183"
Table 3. In addition, for CYP2B6 516G→T, beta coefficients for total cholesterol, LDL cholesterol, 184"
HDL cholesterol, and triglycerides were generally consistent and in the same direction as beta 185"
coefficients for log10 plasma efavirenz concentrations for these parameters. There were trends toward 186"
significant associations between CYP2B6 516G→T and HDL cholesterol concentrations, and between 187"
composite 516/983 genotype and total and HDL cholesterol concentrations.  188"
DISCUSSION 189"
We investigated whether plasma efavirenz concentrations correlated with plasma lipid and/or glucose 190"
concentrations in HIV-infected South Africans. Higher plasma efavirenz concentrations were 191"
associated with significantly higher plasma fasting lipid concentrations and higher glucose 192"
concentrations in 106 HIV-infected South African adults receiving ART in multivariate analyses. In a 193"
subset of 57 participants with available CYP2B6 genotype data, associations between slow metabolizer 194"
genotypes and metabolic profiles were generally consistent with associations based on measured 195"
efavirenz concentrations.  196"
To our knowledge, this is the first report of positive associations between plasma efavirenz 197"
concentrations and LDL cholesterol, or glucose concentrations. Our findings are consistent with a 198"
previous study that showed an association between plasma efavirenz concentrations and fasting HDL 199"
cholesterol in 34 participants,21 but disagree with a retrospective study that found no associations 200"
between plasma efavirenz concentrations and either fasting HDL cholesterol or triglycerides in 59 201"
participants.22  202"
The advent of ART has greatly reduced morbidity and mortality among HIV-infected patients.23 203"
However, the D:A:D (Data Collection on Adverse Events of Anti-HIV Drugs) study showed that 204"
patients treated with protease inhibitors or NNRTIs, alone or in combination, have elevated total 205"
cholesterol, after controlling for known risk factors such as age, BMI and sex.24 Some of these 206"
abnormalities, notably LDL cholesterol and glucose, are associated with an increased risk of vascular 207"
disease in the general population.25,26 208"
The prevalence of metabolic complications in our cohort was high (dysglycaemia 37% and 209"
dyslipidaemia 47%). The commonest dyslipidaemia we found was low HDL cholesterol in 49%, which 210"
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is lower than the 71% we found in ART-naïve patients drawn from the same clinics as the participants 211"
in our study (JA Dave, MBChB PhD, unpublished data, November 2015). However, high LDL 212"
cholesterol and high triglycerides, which were common in our study population, were rare in ART-213"
naïve patients. High prevalence of both dyslipidaemia and dysglycaemia in patients on ART has also 214"
been reported from other African countries.27-29  215"
There is considerable interindividual variability in plasma efavirenz exposure, approximately 34% of 216"
which is explained by three CYP2B6 loss-of-function polymorphisms, CYP2B6 516G→T, 983T→C, 217"
and 15582C→T.10,20 Among South Africans, minor allele frequencies of CYP2B6 516G→T, 983T→C, 218"
and 15582C→T have been reported to be 0.36, 0.07, and 0.09, respectively.20 Both 516G→T and 219"
983T→C are more frequent with African than with European ancestry. The CYP2B6 983T→C allele is 220"
found almost exclusively with African ancestry,11 and has a somewhat greater effect on efavirenz 221"
concentrations per allele than does 516G→T, whereas 15582C→T has a much lesser effect than 222"
516G→T. The lower prevalence of CYP2B6 slow metabolizer genotypes with European ancestry may 223"
explain, in part, why some studies conducted largely in Europeans have not shown associations 224"
between efavirenz and cardiovascular risk.30,31 In our study, the smaller number of participants with 225"
genotype data may have limited our ability to identify statistically significant genetic associations.    226"
Our results have potential public health implications. Efavirenz is the preferred third drug, in 227"
combination with NRTIs, as first line therapy in resource-limited settings where the HIV-1 burden is 228"
greatest.1 Efavirenz may be more likely to result in an increased risk of cardiovascular events among 229"
populations in whom CYP2B6 slow metabolizer genotypes are prevalent. However, higher efavirenz 230"
concentrations were also associated with higher HDL cholesterol in our study, which has been 231"
associated with decreased risk of cardiovascular events. Newer agents such as rilpivirine and 232"
dolutegravir have little or no effect on lipids,32,33 these drugs are currently not available in most low-233"
middle income countries.  234"
Our study has several limitations. Because it is a cross sectional study, we cannot compare changes 235"
from baseline in lipid or glucose concentrations in patients starting ART. The viral load data was 236"
determined by reviewing medical records and only 34 participants had viral load data recorded. 237"
Therefore, viral load was not included in our multivariate analyses.  Our sample size is relatively small. 238"
We investigated associations with mid-dose interval efavirenz concentrations and metabolic 239"
parameters, but other pharmacokinetic parameters (e.g. area under the concentration-time curve) might 240"
better describe the relationships with metabolic profiles. Although participants recorded the time of last 241"
dose on the day before pharmacokinetic sampling, we cannot exclude incomplete adherence. 242"
CONCLUSION 243"
In conclusion, higher plasma efavirenz concentrations were associated with higher plasma lipid and 244"
glucose concentrations.  However, larger cohort studies are needed to replicate these associations. 245"
Well-powered studies in Africa and other regions where efavirenz slow metabolizer genotypes are 246"
prevalent are needed to assess whether long-term efavirenz use is associated with increased risk of 247"
cardiovascular events. 248"
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Figure 1. Scatter plots of log10 transformed plasma efavirenz concentrations (µg/mL) and the 378"
lipid and glucose concentrations in 106 participants. The x-axes represent log10 transformed plasma 379"
efavirenz concentrations. The y-axes represent concentrations of each metabolic parameter [(a): fasting 380"
total cholesterol, (b): fasting triglycerides, (c): fasting HDL cholesterol, (d): fasting LDL cholesterol, 381"
(e): fasting glucose, and (f): glucose 2 hours post oral glucose tolerance test]. Each black marker 382"
denotes an individual lipid or glucose concentration plotted against the plasma efavirenz concentrations 383"
in 106 participants. The solid black line indicates the regression line, with the 95% confidence interval 384"
shown in dotted lines. The equations for the regression line (with the slope and y intercept), correlation 385"




SUPPLEMENTAL DIGITAL CONTENT LEGEND 390"
Supplemental Digital Content 1. Table that illustrates the multivariate regression analyses adjusting 391"
for age, sex, body mass index, total duration on ART, and current stavudine use.  392"
 393"
Supplemental Digital Content 2.  Figure that illustrates a bar graph displaying CYP2B6 genotype 394"
frequencies in 57 South African adults.  395"
 396"
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Table 1. Study participant characteristics 
Variable  Median (IQR) or n/N(%) N 
Age (years) 38 (31 to 45) 106 
Male: Female 29:77 106 
Weight (kg) 69 (60 to 78) 106 
Body mass index (kg/m2) 26 (23 to 30) 106 
Waist: hip ratio 0.89 (0.85 to 0.93) 106 




113 (101 to 125) 




CD4+ T-cell count (cells/ mm3) 
  Pre-ART 
  Current  
 
94 (43 to 153) 




Plasma HIV-1 RNA <400 copies/mL (%) 28/34 (82%) 34 
Total duration on ART (months) 18 (10 to 27) 106 
Concurrent ART n/N (%) 
  Zidovudine/lamivudine 







Any stavudine exposure 99/106 (93%) 106 
Metabolic parameters (mmol/L) 
 Fasting total cholesterol 
 Fasting LDL cholesterol 
 Fasting HDL cholesterol 
 Fasting triglycerides  
 Fasting glucose 
 2-hour post OGTT glucose  
 
4.76 (3.95 to 5.65) 
3.08 (2.32 to 3.77) 
1.05 (0.81 to 1.30) 
1.26 (1.01 to 1.79) 
5.20 (4.80 to 5.80) 








 IQR= interquartile range, n/N = number of participants with variable of interest/total number of the study 
population, ART= antiretroviral therapy, HIV=Human Immunodeficiency Virus, RNA= ribonucleic acid, 
LDL= low-density lipoprotein, HDL= high-density lipoprotein, OGTT= oral glucose tolerance test. 
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Scatter plots oflog10 transformed plasma efavirenz concentrations (µg/mL) and the lipid and glucose 
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Table 2. Multivariate linear regression analyses (each adjusted for age, body mass index and total 
duration on ART) between log10 transformed efavirenz mid-dosing interval concentrations and each 
metabolic parameter (N=106) 
Outcome variable β  (95%CI) *Mean change (95% CI) per 
doubling of efavirenz 
concentrations (mmol/L) 
p-value 
Total cholesterol 1.34 (0.73 to 1.95) 0.40 (0.22 to 0.59) 0.000 
LDL cholesterol 0.62 (0.14 to 1.01) 0.19 (0.04 to 0.30) 0.012 
HDL cholesterol 0.46 (0.24 to 0.67) 0.14 (0.07 to 0.20) 0.000 
Triglycerides 0.58 (0.09 to 1.08) 0.17 (0.03 to 0.33) 0.022 
Fasting glucose 0.60 (0.11 to 1.10) 0.18 (0.03 to 0.33) 0.017 
2-hour glucose 1.14 (0.28 to 2.00) 0.34 (0.08 to 0.60) 0.010 
ART= antiretroviral therapy, N = total number of the study population, LDL= low-density lipoprotein, HDL = high-density 
lipoprotein. *Mean change (95%CI) in lipid and glucose concentrations (in mmol/L) with doubling of efavirenz concentrations. The 
mean changes are calculated using the formula Y= β*log10 (2), where β is the beta coefficient for the log10 transformed efavirenz 
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Supplementa1 Table 1. Multivariate linear regression analyses (each adjusted for age, body mass 
index, total duration on ART and current stavudine use) between log10 transformed efavirenz mid-
dosing interval concentrations and each metabolic parameter (N=106) 
 
 
Outcome variable β  (95%CI) *Mean change (95% CI) per 
doubling of efavirenz 
concentrations (mmol/L) 
p-value 
Total cholesterol 1.31 (0.70 to 1.93) 0.39 (0.21 to 0.58) 0.000 
LDL cholesterol 0.60 (0.12 to 1.08) 0.18 (0.04 to 0.32) 0.015 
HDL cholesterol 0.45 (0.23 to 0.67) 0.14 (0.07 to 0.20) 0.000 
Triglycerides 0.59 (0.09 to 1.09) 0.18 (0.03 to 0.33) 0.020 
Fasting glucose 0.59 (0.08 to 1.09) 0.18 (0.02 to 0.33) 0.023 
2-hour glucose 1.10 (0.21 to 1.99) 0.33 (0.06 to 0.60) 0.016 
ART= antiretroviral therapy, N = total number of the study population, LDL= low-density lipoprotein, HDL = high-density 
lipoprotein. *Mean change (95%CI) in lipid and glucose concentrations (in mmol/L) with doubling of efavirenz concentrations. The 
mean changes are calculated using the formula Y= β*log10 (2), where β is the beta coefficient for the log10 transformed efavirenz 
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Supplemental Figure 1. Bar graph displaying CYP2B6 genotype frequencies in 57 South African adults. 
The x-axis represents CYP2B6 genotypes: 15582C-T (solid black), CYP2B6 516G-T (dark grey), 983T-C 
Qight grey), composite 516/983 (black and white squares), and composite 15582/516/983 (black and white 
horiwntal lines) genotypes. The composite genotypes were categorized into three levels; extensive metabolizer 
(EXT), intennediate metabolizer (INT) and slow metabolizer (SLO). The y-axis represents genotype frequencies in 
percentages. The number in italics at the top of each bar displays the absolute count. a Composite 516/983 were 
assigned as follows: EXT (516GG-983TT); INT (516GT-983TT or 516GG-983CT); and SLO (516TT-983TT, 
516GT-983CT). b Composite 15582/516/983 were assigned as follows: EXT (15582CC-516GG-983TT or 
15582CT-516GG-983TT); INT (15582TT-516GG-983TT, 15582CC-516GT-983TT, 15582CC-516GG-983CT, 
15582CT-516GT-983TT, or 15582CT-516GG-983CT); and SLO (15582CC-516TT-983TT, 
15582CC-516GT-983CT). 
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0.46 (0.02 to 0.90) 
0.048 
-0.22 (-1.01 to 0.66) 
0.634 
-0.02 (-1.01 to 0.66) 
0.965 
0.39 (-0.05 to 0.83) 
0.091 




0.21 (-0.14 to 0.56) 
0.243 
-0.08 (-0.75 to 0.60) 
0.828 
0.20 (-0.39 to 0.80) 
0.506 
0.18 (-0.16 to 0.25) 
0.300 





0.13 (-0.01 to 0.27 
0.065 
-0.01 (-0.31 to 0.24) 
0.799 
-0.07 (-0.31 to 0.17) 
0.556 
0.12 (-0.02 to 0.25) 
0.093 
0.10 (-0.03 to 0.24) 
0.150 
Triglycerides 
0.26 (-0.04 to 0.56) 
0.104 
-0.23 (-0.82 to 0.37) 
0.456 
-0.33 (-0.85 to 0.20) 
0.228 
0.19 (-0.11 to 0.49) 
0.228 
0.17 (-0.14 to 0.48) 
0.282 
Fasting glucose 
0.36 (-0.17 to 0.34) 
0.495 
-0.21 (-0.72 to 0.29) 
0.412 
0.03 (-0.42 to 0.48) 
0.896 
0.03 (-0.23 to 0.29) 
0.802 
-0.01 (-0.27 to 0.26) 
0.962 
2 hour glucose 
-0.04 (-0.71 to 0.64) 
0.919 
-0.59 (-1.87 to 0.67) 
0.373 
-0.18 (-1.13 to 0.97) 
0.755 
-0.19 (-0.85 to 0.47) 
0.579 


































itle and abstract 
1 




 in the title or the abstract 
3 
(b) Provide in the abstract an inform





























escribe the setting, locations, and relevant dates, including periods of recruitm
ent, exposure, follow







ive the eligibility criteria, and the sources and m








ive the eligibility criteria, and the sources and m
ethods of case ascertainm
ent and control selection. G
ive the 




ive the eligibility criteria, and the sources and m
ethods of selection of participants 




atched studies, give m
atching criteria and num




atched studies, give m
atching criteria and the num






learly define all outcom
es, exposures, predictors, potential confounders, and effect m
odifiers. G

















ethods if there is m











 the study size w






 quantitative variables w
ere handled in the analyses. If applicable, describe w
hich groupings w







escribe all statistical m




ethods used to exam









If applicable, explain how





If applicable, explain how
 m








If applicable, describe analytical m
ethods taking account of sam
pling strategy 
(e) D
escribe any sensitivity analyses 
5 





















bers of individuals at each stage of study—
eg num
bers potentially eligible, exam
ined for eligibility, confirm
ed eligible, 
included in the study, com
pleting follow
-up, and analysed 
6 
(b) G
ive reasons for non-participation at each stage 
 
(c) C








ive characteristics of study participants (eg dem
ographic, clinical, social) and inform
ation on exposures and potential confounders 
6, Table 1 
(b) Indicate num
ber of participants w
ith m






























bers in each exposure category, or sum
m
ary m

















ates and, if applicable, confounder-adjusted estim
ates and their precision (eg, 95%








Table 2, 3 
(b) R
eport category boundaries w
hen continuous variables w
ere categorized 
5 
(c) If relevant, consider translating estim








eport other analyses done—









arise key results w







itations of the study, taking into account sources of potential bias or im
precision. D
iscuss both direction and m






ive a cautious overall interpretation of results considering objectives, lim
itations, m
ultiplicity of analyses, results from
 sim
ilar studies, and 














ive the source of funding and the role of the funders for the present study and, if applicable, for the original study on w
hich the present 







ation separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. N
ote: A
n Explanation and 
Elaboration article discusses each checklist item
 and gives m
ethodological background and published exam
ples of transparent reporting. The STR
O
B
E checklist is best used in conjunction w
ith this 
article (freely available on the W


















ation on the STR
O
B







Conclusions            
!
134
Chapter 7  
Conclusions 
Improved access to ART has led to the decline in HIV associated morbidity and mortality. 
However, cumulative exposure to antiretroviral therapy (ART) has been associated with 
metabolic adverse effects such as dyslipidaemia, insulin resistance, dysglycaemia, central fat 
accumulation, peripheral fat loss (lipoatrophy), and peripheral neuropathy.  
This thesis collection of studies nested within a cross-sectional study that enrolled ambulant HIV 
infected participants in Cape Town between 2007-2009. The details of the main study are 
described in the introduction and elsewhere.1 The aim of the main study was to determine the 
prevalence of DSP, dysglycaemia, dyslipidaemia, hyperlactataemia and lipodystrophy. We 
collected clinical and laboratory data from HIV infected patients on ART from Cape Town. We 
sequenced the mitochondrial genome and determined African mtDNA haplogroups. We 
genotyped 241 polymorphisms in genes potentially relevant to efavirenz metabolism and 
transport. We measured steady state efavirenz and lopinavir concentrations and used regression 
analyses to determine associations with metabolic parameters.  
This thesis presents studies that investigated associations between plasma lopinavir 
concentrations and lipid and glucose concentrations (Chapter 3), explored associations of 
mitochondrial DNA (mtDNA) haplogroups and ART related metabolic complications (chapter 4), 
characterized relationships between genetic polymorphisms and plasma efavirenz concentrations 
(chapter 5), and investigated associations between plasma efavirenz concentrations and lipid and 
glucose concentrations (chapter 6) in HIV-infected Black South Africans.  
The study in Chapter 3 reported data on 84 black South African HIV-infected adults treated with 
ritonavir-boosted lopinavir for a median duration of 19 months, had lopinavir trough 
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concentrations measured and the associations with lipids and glucose concentrations were 
investigated. To our knowledge, this is the first study to investigate the association between 
lopinavir concentrations and serum lipids or glucose concentrations in a South African 
population. There was a high prevalence of dyslipidaemia (29%) and dysglycaemia (42%).  
Despite that, there were no significant associations between plasma lopinavir concentrations and 
lipid or glucose concentrations. There was also no significant association between the lopinavir 
concentrations above the median, and hypercholesterolaemia, hypertriglyceridaemia or 
dysglycaemia. The median lopinavir concentration was 8 µg/mL, which is higher than reported 
elsewhere,2,3 but comparable to the trough concentrations after observed doses in a study 
conducted by our group from the same community.4 Our findings are in contrast with findings 
from a small study conducted in 19 patients, which reported that lopinavir trough concentrations 
were higher in three patients experiencing grade 3 or 4 lipid elevations.5 A second larger study 
(n=126) found that patients with fasting triglyceride concentrations above the median had higher 
lopinavir trough concentrations, but no correlation was found between lopinavir and cholesterol 
concentrations.6 Four other studies reported findings similar to ours, with no association between 
lopinavir and lipids.3,7-9 In one of these studies, the investigators also reported no association 
between lopinavir concentrations and glucose concentrations.8  
The study reported in Chapter 4 explored associations between African mtDNA haplogroups and 
ART-related complications in a cohort of HIV-infected South African adults. In this study, L3e1 
subhaplogroup was significantly associated with hypertriglyceridemia independent of 
lopinavir/ritonavir exposure. This is the first report to link an African mtDNA variant to 
hypertriglyceridemia. We found no associations between mtDNA haplogroups and other 
metabolic complications, including hypercholesterolemia, dysglycemia, lipoatrophy, or DSP. 
We also described the frequencies of the mitochondrial haplogroups in our South African cohort 
recruited from two Cape Town clinics, the majority of which belonged to the L0 haplogroup. 
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There are limited data regarding the distribution of the mitochondrial haplogroups in the South 
African population. However, the distribution of mitochondrial haplogroups we found was 
similar to a recently published South African study conducted in 71 children.10 None of the 
participants analyzed belonged to the European mitochondrial haplogroups. 
The association between L3e1 subhaplogroup and hypertriglyceridemia was independent of 
LPV/r use, which is a well-documented cause of elevated triglycerides.11 In a recent study of 174 
non-Hispanic white HIV-infected clinical trial participants in the United States, the European 
mtDNA haplogroup I was associated with a decrease in triglycerides over 96 weeks of ART when 
compared with non-I mtDNA haplogroups.12 To the best of our knowledge, the association 
between African mtDNA haplogroups and hypertriglyceridemia has not previously been studied. 
An association between an mtDNA polymorphism and plasma triglycerides was previously 
reported in a Canadian cohort.13 Variation at mtDNA position 16517 was associated with 
significantly higher fasting plasma triglyceride concentrations in this population. These data 
support the hypothesis that mitochondrial DNA variation may influence fatty acid and lipid 
metabolism. Fatty acids derived from plasma triglycerides are precursors of acyl CoA, which is 
used in the mitochondrial ß oxidation cycle of fatty acid metabolism. Genetic variation affecting 
mitochondrial function might also affect the utilization of fatty acid in ß oxidation.13 Differences 
in cellular utilization may then alter the demand of fatty acids from triglycerides, which may 
influence plasma concentrations.13 However, the exact mechanism is still unclear. 
Finally, we found no association between African mtDNA haplogroups and DSP. A study 
conducted in non-Hispanic black participants from ACTG study 384 reported an association 
between the African mtDNA L1c and increased susceptibility to peripheral neuropathy during 
NRTI treatment.14 As discussed above, the L1 haplogroup was found in only three participants in 
our cohort and they were excluded from our analyses, so we were unable to replicate this reported 
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association. Here, DSP was frequent and no association was observed with a particular 
haplogroup. We were also unable to adjust for the effect of d-drugs, an important cause of DSP, 
as >90% of participants had been exposed to stavudine and/or didanosine. All participants were 
examined by either of two trained clinicians, and DSP was more rigorously defined compared 
with many other reports. The prevalence of DSP in our cohort was high (66%), compared with 
that reported in the ACTG study (33%).14 Since the publication of this study, a study conducted in 
Malawians reported an associations between peripheral neuropathy and L0a2 (increase 
susceptibility) and L2a (protective). The discrepant results can be explained by differences in the 
haplogroup frequencies between the two African countries as well as the different ways of 
phenotype ascertainment resulting in a remarkable difference in DSP prevalence (25% vs 66% in 
our study). Kampira et al based their case definition of DSP on symptoms, which may misclassify 
subjects with asymptomatic DSP and controls, while our study defined DSP after neurological 
examination and symptoms. 
In Chapter 5, the pharmacogenetics study of efavirenz exposure in 113 HIV-infected black South 
African adults and children is reported. Efavirenz is one of the most extensively prescribed 
medications worldwide for HIV-1 infection, and multiple previous studies have associated 
CYP2B6 516 G→T, and CYP2B6 983 T→C with increased plasma efavirenz concentrations.15 
Our study replicated these associations in Black South Africans. In addition, we show for the first 
time that CYP2B6 15582C→T is also associated with plasma efavirenz concentrations in Black 
South Africans, which had previously only been reported for efavirenz in one study from the 
United States.16 In univariate analyses, a model that included composite genotype (CYP2B6 
516/983/15582) best predicted efavirenz concentrations. These associations were consistent in 
adults and children. An association between CYP2B6 15582C→T and slower plasma drug 
clearance has also been reported among Cambodians for the CYP2B6 substrate nevirapine,17 
further supporting the validity of our finding.  We did not find significant associations beyond 
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CYP2B6 516G→T, 983T→C, and 15582C→T. Although one analysis suggested an association 
with NR1I2 rs9847782, this was no longer apparent after excluding one outlier, suggesting a 
spurious association. Our study also provides information regarding minor allele frequencies for 
ABCB1, CYP2A6, CYP2B6, CYP3A4, NR1I2 and NR1I3 polymorphisms in a South African 
population. 
We observed lower efavirenz concentrations in children, which are probably explained by the 
faster rate of drug metabolism in children compared with adults.18 High prevalence of low 
efavirenz concentrations in children have also been attributed to the current weight based WHO 
guidelines, and have been observed in a South African population similar to ours.19 We assessed 
associations between polymorphisms and efavirenz concentrations separately in adults and 
children. In both children and adults, CYP2B6 516G→T had the strongest overall association 
with efavirenz concentrations, although CYP2B6 983T→C had the greatest effect size per allele. 
The association with CYP2B6 15582C→T could not be demonstrated in adults and children 
analyzed separately, possibly due to smaller samples sizes.  
In this study, minor allele frequencies of CYP2B6 516G→T, 983T→C, and 15882C→T were 
0.36, 0.07, and 0.09, respectively. In the multivariate regression model including all three 
polymorphisms, CYP2B6 983T→C had the greatest magnitude of effect on log10 efavirenz 
concentrations (β=0.38 for 983T→C, β=0.27 for 516G→T, β=0.06 for 15882C→T), but due to 
lower frequency only explained approximately 8% of variance in univariate analysis, versus 19% 
for 516G→T, and negligible effect for 15882C→T. In sensitivity analyses that excluded two 
individuals with extreme outlier efavirenz concentrations, the variance explained by all three 
polymorphisms increased from 34% to 45%. 
In chapter 6, we investigated whether plasma efavirenz concentrations correlated with plasma 
lipid and/or glucose concentrations in HIV-infected South Africans. Higher plasma efavirenz 
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concentrations were significantly associated with higher plasma fasting lipid concentrations and 
higher glucose concentrations in 106 HIV-infected South African adults receiving ART in 
multivariate analyses. In a subset of 57 participants with available CYP2B6 genotype data, 
associations between slow metabolizer genotypes and metabolic profiles were generally 
consistent with associations based on measured efavirenz concentrations. To our knowledge, this 
is the first report of positive associations between plasma efavirenz concentrations and LDL 
cholesterol, or glucose concentrations. Our findings are consistent with a previous study that 
showed an association between plasma efavirenz concentrations and fasting HDL cholesterol in 
34 participants,20 but disagree with studies that found no associations between plasma efavirenz 
concentrations and either fasting HDL cholesterol.21,22 
In summary, the four studies have significantly contributed to the field of HIV research in the 
following ways:  
First, we investigated associations between lopinavir and efavirenz drug concentrations and 
metabolic complications. This is the first time these associations, or lack thereof, have been 
described in an African population from Sub-Saharan region, the region hardest hit by the HIV 
burden. In children aged ≥3 years and adults, the World Health Organization (WHO) 
recommends combination ART consisting of a nucleoside (nucleotide) reverse transcriptase 
inhibitor (NRTI) backbone with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) 
or a ritonavir-boosted protease inhibitor (PI) for first and second line regimens.23 The finding that 
efavirenz concentrations positively correlated with lipids and glucose could increase long term 
risk of cardiovascular disease, which important public health implications for screening for risk 
factors or for selecting safer antiretrovirals.   
Second, we describe the mitochondrial DNA haplogroup frequencies in Black South Africans. 
This highlights the differences in the most prevalent haplogroups between African-Americans 
and South Africans, or between South Africans and Malawians.14,24 For example, in African-
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Americans subhaplogroup L1c was reported to increase susceptibility to peripheral neuropathy.14 
In 171 participants enrolled in our study, only 3 people belonged to haplogroup L1 and were 
excluded from analyses. More importantly, we describe a novel association between African 
mitochondrial subhaplogroup L3e1 and hypertriglyceridaemia. This finding was independent of 
the well-described association between lopinavir and hypertriglyceridaemia. This finding has yet 
to be replicated. We found no associations between mtDNA haplogroup and other features of 
mitochondrial toxicity due to NRTIs (DSP, lipoatrophy and lactate) 
Third, we described minor allele frequencies of 241 single nucleotide polymorphisms in genes 
relevant to efavirenz metabolism and drug transporters. We provide evidence to show that 
CYP2B6 15582C→T is associated with plasma efavirenz concentrations in Black South Africans, 
in addition to CYP2B6 516G→T and 983T→C. We show that genetic associations are consistent 
in adults and children. We also found no additional associations with plasma efavirenz 
concentrations beyond these CYP2B6 polymorphisms. As efavirenz is still recommended as first 
line regimen for children aged ≥3 years and adults, in Sub-Saharan Africa, where the HIV burden 
is the highest, and both CYP2B6 516G→T and 983T→C alleles are more frequent, these patients 
are more likely to have higher efavirenz concentrations, and are at increased risk of adverse 
events.  
Fourth, we explored associations in a subset of participants with CYP2B6 516/983/15582 
composite genotype data and lipids and glucose concentrations. We found that in CYP2B6 slow 
metabolizer, lipids and glucose concentrations tended to be higher. This needs further exploration 
in larger studies. 
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Limitations of the studies 
The findings from these studies need to be interpreted within the context of their limitations. For 
the studies investigating associations between drug concentration and lipids and glucose 
(chapters 3 and 6) the limitations are as follows: First, the cross sectional study design limited 
the ability to compare baseline lipid or glucose concentrations prior to ART start. Second, 
patients with known diabetes or dyslipidaemia were excluded from the study. However, this is 
unlikely to have made a difference as only a small number were excluded. Third, the timing of 
the doses of lopinavir or efavirenz was not observed. To minimize recall bias, participants were 
requested to record the time of last dose on the appointment card for the day before 
pharmacokinetic sampling. Adherence was self-reported. Therefore, incomplete adherence cannot 
be excluded, which could have important effects on the observed concentrations. Fourth, we used 
lopinavir trough and efavirenz mid-dosing interval concentrations and not the area under the 
curve, the pharmacokinetic parameter that better describes the drug exposure. Fifth, viral load 
was missing in the majority of participants and therefore could not be used as a covariate in 
multivariate analyses. Sixth, the sample size may have limited our ability to find associations 
between lopinavir and lipids and glucose. However, it should be noted that our study was larger 
than most other studies that explored these associations.    
The study reported in chapter 4 that investigated an association between African mtDNA and 
metatabolic complications had similar limitations to those decribed above. The design was cross-
sectional, with participants of different HIV disease stages and different ART durations. We 
excluded ART-naive participants and participants with current opportunistic infections, known 
hepatic or renal disease, or with known dyslipidemia (or taking lipid-lowering therapy) or 
dysglycemia (or taking antidiabetic drugs). Viral load data were missing in the majority of 
participants, and were therefore not included in the analysis as a covariate. The sample size was 
relatively small and we did not formally adjust for multiple comparisons. However, when 
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considering the five mtDNA subhaplogroups we analyzed, only the unadjusted analyses between 
subhaplogroup L3e1 and triglycerides concentrations (Wilcoxon p=0.003), or 
hypertriglyceridemia (p=0.007) remained significant when our level of significance was 
corrected to p<0.01. 
The study in chapter 5 investigated 241 single nucleotide polymporhisms in 113 participants. 
Sample size limited our ability to extensively identify novel genetic associations with efavirenz 
concentrations. We pooled analyses between adults and children to improve power, and 
associations in this pooled analysis were similar to those in adults and children analyzed 
separately. In addition, because the dose of efavirenz was not observed, we could not be certain 
of dose-sampling times.  
Implications for HIV research 
In chapter 3, we did not find associations between lopinavir concentrations and lipids and 
glucose concentrations. Larger prospective studies are needed to establish whether the association 
exists between lopinavir concentrations and increasing lipids or glucose concentrations. We found 
high lopinavir concentrations in our cohort, a finding similar to a study conducted from the same 
population.4 Lopinavir has large interindividual pharmacokinetic variability, at least part of which 
can be explained by age, sex, body weight, drug-drug interactions, liver disease, pregnancy and 
poor adherence.25 The remaining variability is attributed to host genetic factors. Gene-gene 
interactions between genetic polymorphisms that influence lopinavir pharmacokinetics and the 
development of dysglycaemia or dyslipidaemia should be explored. 
 In chapter 4,  we observed a novel association between African mtDNA subhaplogroup L3e1 
and hypertriglyceridemia. We did not find associations between African mtDNA haplogroups and 
the other ART-related complications studied, but we may have been underpowered to identify 
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smaller associations. Larger studies in sub-Saharan Africa, which has the highest HIV burden in 
the world but few pharmacogenomic studies, are needed to confirm the association we found 
between African mtDNA subhaplogroup L3e1 and hypertriglyceridemia, and to explore 
associations between mtDNA haplogroups and other HIV- and ART-related complications. If the 
association between L3e1 and hypertriglyceridemia is confirmed, functional studies are needed to 
unravel the mechanism by which this subhaplogroup may increase triglycerides. 
The study in chapter 5 improves the understanding of genetic determinants of efavirenz plasma 
exposure in an African population, including adults and children. Studies of associations between 
efavirenz concentrations and polymorphisms in African populations should consider CYP2B6 
516G→T and 983T→C, and ideally also 15582C→T. 
The study in chapter 6 showed that higher plasma efavirenz concentrations were associated with 
higher plasma lipid and glucose concentrations.  Larger prospective cohort studies are needed to 
replicate these associations. Well-powered studies in Africa and other regions where efavirenz 
slow metabolizer genotypes are prevalent are needed to assess whether long-term efavirenz use is 
associated with increased risk of cardiovascular events.!
Implications for clinical practice 
Our findings improve the understanding of genetic determinants of efavirenz plasma exposure in 
an African population, and provide new insights into host factors associated with ART related 
metabolic complications. Some of our study findings have potential public health implications.  
Efavirenz is the preferred third drug, in combination with NRTIs, as first line therapy in resource-
limited settings where the HIV-1 burden is greatest.23 Efavirenz may be more likely to result in an 
increased risk of cardiovascular events among populations in whom CYP2B6 slow metabolizer 
genotypes are prevalent. However, higher efavirenz concentrations were also associated with 
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higher HDL cholesterol in our study, which has been associated with decreased risk of 
cardiovascular events. Newer agents such as rilpivirine and dolutegravir have little or no effect on 
lipids,26,27 these drugs are currently not available in most low-middle income countries, but there 
is increasing interest in using them, as they are better tolerated than efavirenz.  
In Sub-Saharan Africa, where the CYP2B6 slow metabolizer genotypes are prevalent, and 
efavirenz is likely to continue to be prescribed as the preferred third drug in the medium, reducing 
the doses from 600mg to 400mg in patients is likely to lead to reduced adverse events and 
additionally, be cost saving. Monitoring and managing other risk factors for cardiovascular 
disease is vital. 
The clinical utility of efavirenz genotyping or mitochondrial sequencing still needs further work 
and cannot be recommended based on our findings. Our findings do not support therapeutic drug 
monitoring of lopinavir for the prevention of metabolic complications. The clinical utility and 
cost-effectiveness of monitoring efavirenz concentrations in populations where CYP2B6 slow 
metabolizer genotypes are prevalent still needs to be determined.! !
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